

## **Patterns of age disparities in colon and lung cancer survival: a systematic narrative literature review**

**Sophie Pilleron**, Dept of Public Health, School of medicine, University of Otago, Wellington, New Zealand;  
[sophie.pilleron@otago.ac.nz](mailto:sophie.pilleron@otago.ac.nz)/[sophie.pilleron@gmail.com](mailto:sophie.pilleron@gmail.com)

**Helen Gower**, Surgical Cancer Research Group, Dept of Surgery and Anaesthesia, University of Otago, Wellington, New Zealand; [helen.gower@ccdhb.org.nz](mailto:helen.gower@ccdhb.org.nz)

### **Maryska Janssen-Heijnen**

Department of Clinical Epidemiology, VieCuri Medical Centre, Venlo, The Netherlands;

Department of Epidemiology, Maastricht University Medical Centre+, GROW School for Oncology and Developmental Biology, Maastricht, The Netherlands

[mjanssenheijnen@viecuri.nl](mailto:mjanssenheijnen@viecuri.nl)

**Virginia Signal**, Dept of Public Health, School of medicine, University of Otago, Wellington, New Zealand;  
[virginia.signal@otago.ac.nz](mailto:virginia.signal@otago.ac.nz)

**Jason Gurney**, Dept of Public Health, School of medicine, University of Otago, Wellington, New Zealand;  
[Jason.gurney@otago.ac.nz](mailto:Jason.gurney@otago.ac.nz)

**Eva JA Morris**, Nuffield Department of Population Health, University of Oxford, Big Data Institute, Old Road Campus, Oxford, OX3 7LF, UK; [eva.morris@ndph.ox.ac.uk](mailto:eva.morris@ndph.ox.ac.uk)

**Ruth Cunningham**, Dept of Public Health, School of medicine, University of Otago, Wellington, New Zealand;  
[ruth.cunningham@otago.ac.nz](mailto:ruth.cunningham@otago.ac.nz)

**Diana Sarfati**, New Zealand cancer control agency, Wellington, New Zealand;

[diana.sarfati@cancercontrolagency.govt.nz](mailto:diana.sarfati@cancercontrolagency.govt.nz)

**Corresponding author:** Sophie Pilleron, Department of Public Health, University of Otago, PO Box 7343, Wellington, New Zealand. Phone: +64 4 918 6661; email: [sophie.pilleron@otago.ac.nz](mailto:sophie.pilleron@otago.ac.nz)/[sophie.pilleron@gmail.com](mailto:sophie.pilleron@gmail.com)

Word count: 3615

## Abstract

**Objective:** To identify patterns of age disparities in cancer survival, using colon and lung cancer as exemplars.

**Methods:** We conducted a systematic review of literature published in EMBASE, MEDLINE, Scopus, and Web of Science according to PRISMA guidelines. We included population-based studies in patients with colon or lung cancer. We assessed the quality of included studies against selected evaluation domains from the QUIPS Tool, and items concerning statistical reporting. We evaluated age disparities using the absolute difference in survival or mortality rates between middle-aged group and the oldest age group, or by describing survival curves.

**Results:** Out of 2,162 references reviewed, we retained 35 studies (15 for colon, 18 for lung, 2 for both sites). Regardless of the cancer site, included studies were highly heterogeneous and often of poor quality. The magnitude of age disparities in survival varied greatly by sex, ethnicity, socio-economic status, stage at diagnosis, cancer site and morphology, the number of nodes examined, and by treatment strategy. Although results were inconsistent for most characteristics, we consistently observed greater age disparities for females with lung cancer compared to males. Also, age disparities increased with more advanced stages for colon cancer, and decreased with more advanced stages for lung cancer.

**Conclusions:** Although age is one of the most important prognostic factors in cancer survival, age disparities in colon and lung cancer survival have so far been understudied in population-based research. Further studies are needed to better understand age disparities in colon and lung cancer survival. (PROSPERO registration number: CRD42020151402).

**Keywords:** colon cancer, lung cancer, survival, age disparities, literature review

## Article Summary

### Strengths and limitations of this study

- For the first time, we conducted a systematic review of population-based studies relating to differences in cancer survival between middle-aged and older patients, using colon and lung cancer as exemplar cancers.
- We limited our search to peer-reviewed original articles and letters to Editors published in English up until 30 September 2019.
- We excluded clinical studies and trials because of the strict selection of patients and the common underrepresentation of older patients in these studies.
- We could not conduct any quantitative analysis (such as meta-analysis) because of the vast heterogeneity of studies included, which prevented us from quantifying the relationship between increasing age and cancer survival.

## Introduction

Poorer cancer survival among older patients has been well documented<sup>1-6</sup>. Although patients with cancer are increasingly surviving their disease thanks to advances in treatment<sup>2-6</sup>, those who are older have not benefitted from these advances to the same magnitude as their middle-aged counterparts, widening the age-related cancer survival gap<sup>2,5,7</sup>.

From a clinical point of view, cancer management in older patients may be different to that of middle-aged patients due to higher comorbidity levels, polypharmacy, age-related physiological changes, and reduced life expectancy<sup>8</sup>. In addition, older adults with cancer are often excluded from randomised clinical trials, limiting the evidence they provide in relation to the benefits and risks of different treatment strategies at older ages<sup>9,10</sup>. Cancer management may also be hindered in older cancer patients by social factors such as reduced social support<sup>11,12</sup> or healthcare system-related factors such as access to care facilities.

A recent systematic review found that advanced age, low income, low socioeconomic status, presence of comorbidities, advanced stage, and poor tumor grade were associated with lower survival among older adults with cancer, while female gender and being married were associated with better survival<sup>13</sup>. However, the authors did not explore inequalities in cancer survival between age groups, and they excluded studies that included middle-aged patients. They also did not focus on any particular cancer sites. This is important, as it is likely that many factors at different levels (e.g. patient level, health care system level) influence age disparities in cancer survival, and they may vary depending on cancer site.

Worldwide, colon and lung cancers are the most common cancer types diagnosed among adults aged 65 years and older<sup>14</sup>. These two cancer sites have different biology, risk factors and survival outcomes, with colon cancer having a higher five-year relative survival than lung cancer, ranging from 59%-71% for colon cancer and 15%-22% for lung cancer in high-income countries<sup>7</sup>. These cancers also have a different pattern of age inequalities in survival over time. In colon cancer, disparities in cancer survival between older and younger adults is mainly observed in the first year following diagnosis, while in lung cancer, the excess mortality in older adults is mainly observed after five years of follow-up<sup>5,15</sup>.

To our knowledge, there has been no attempt to summarise the available literature on age disparities in cancer survival. Thus, in this manuscript we conducted a systematic review of studies that have investigated differences

in cancer survival between middle-aged and older patients, using the diverse contexts of colon and lung cancer as exemplars. We aimed to identify i) patterns of age-related disparities based on patient and clinical characteristics and ii) the potential gaps in knowledge to inform future research.

## **Methods and materials**

We conducted a systematic literature search of EMBASE, MEDLINE, Scopus, and Web of Science. Using a Boolean approach, we searched for articles including the following keywords: cancer, colon, lung, survival, and older patients. **Supplementary Table 1** shows the search terms that were used. The search strategy was first set up in EMBASE (**Supplementary Table 2**), and then adapted for the other databases.

We retained all original articles or letters published in English up until 30 September 2019 that included patients diagnosed with colon or lung cancer. Eligible studies were required to report survival across several age groups (of which at least one was over the age of 65), or investigate the impact of increasing age on survival stratified by at least one other characteristic (e.g. sex, treatment, etc.). We included population-based studies only. We excluded clinical studies and trials because of their strict inclusion criteria and the underrepresentation of older adults<sup>9</sup>. The PICO criteria for our review are shown in **Supplementary Table 3**.

### *Study selection*

We selected eligible articles using a three-step process: (i) after removal of duplicate records, SP screened all titles to remove irrelevant studies, with a 10% random sample of these verified by VS. (ii) For each study retained after title screening, SP screened all abstracts, with a 10% random sample of these checked by HG. (iii) The full text of all retained papers were retrieved and assessed twice for eligibility by SP, with a 10% random sample verified by HG. **Supplementary Table 4** lists all references not included in the final selection after screening the full text, along with the justification of their exclusion. In addition, SP scanned the reference lists of all included studies for additional relevant studies. If one of the authors knew a study that met the eligibility criteria, we included it if relevant. The origin of the studies (i.e. database search or reference lists) are specified in **Supplementary Table 4** for excluded papers, and in **Table 1** for included papers.

### *Data collection process and data items*

For all included studies, SP and HG independently extracted the following information: first author; year of publication; location of data; study objective; cancer type; stage at diagnosis; age at diagnosis; exclusion criteria; cancer diagnosis period; source of cancer data; source of mortality data; measure of age; source of age; sampling; time origin; end of follow-up; survival/mortality metrics; method; sample size; time of follow-up; number of deaths; characteristic(s) studied and their definition.

In cases where an eligible study contained no numerical survival estimates but presented one or more graphs showing survival by age group stratified by another characteristics (e.g. sex, stage at diagnosis, etc.), SP emailed the corresponding author to request numerical data<sup>16-21</sup>.

SP and HG independently assessed the quality of included studies against selected evaluation domains from the QUIPS Tool<sup>22</sup>: study participation; prognostic factor measurement; outcome measurement; and statistical reporting. We adapted the items within each domain to our study. Also, we used selected items among those suggested by Altman et al. to assess statistical reporting<sup>23</sup>.

Where numerical survival estimates were available, we assessed age disparities in survival by calculating the absolute difference in (overall or relative) survival between middle-aged patients (age groups differed depending on the availability of data) and the oldest age group, to give a sense of trends and inform discussion. When survival estimates were available for several periods of cancer diagnosis, we retained estimates for the latest period. Where numerical survival estimates were not available, we described survival curves by age group and the characteristic(s) of interest. For mortality rates, we computed the absolute difference between the mortality rate in the oldest age group with that in the middle-aged age group, again to give a sense of trends and inform discussion. We reported confidence intervals or p-values when available.

We collected and logged references in Zotero 5.0.73. We used the Rayyan free web application for the title and abstract screening<sup>24</sup>. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used for the review<sup>25</sup>, and we registered our review protocol in the International Prospective Register of Systematic Review (PROSPERO registration number: CRD42020151402).

### *Patient and public involvement*

No patient involved.

## Results

We screened 2,162 references for eligibility and retained 35 studies (**Figure 1**): fifteen studies on colon cancer survival<sup>16,17,20,21,26–36</sup>, eighteen on lung cancer survival<sup>18,19,37–52</sup> and two studies on both colon and lung cancer survival<sup>53,54</sup>.

### *Quality assessment (Table 1)*

Essential information to appropriately interpret survival analysis results (*i.e.* the number of events, end of follow-up, numerical estimates of survival) were missing in a substantial proportion of the included studies. For example, fifteen studies did not report the time origin from which the survival time had been calculated<sup>16,20,26,28–32,35–37,41,43,51,52</sup>, and six studies did not indicate the end of follow-up date<sup>29,35,36,41,44,52</sup>. In 28 articles the authors did not report follow-up time<sup>16–21,26–31,35,37–44,46,48,52–54</sup>, and the number of deaths were missing in 26 articles<sup>16,18–21,27–32,35,37–41,43,44,48,49,52–54</sup>. Only three studies reported the source of age at diagnosis (from medical records)<sup>27,30,44</sup>. In seven studies, the authors did not provide numerical survival estimates<sup>16–19,21,26,46</sup>.

### *Characteristics of included studies (Tables 2-5)*

All studies used population-based cancer registry data. Only one study analysed a random sample of patients<sup>26</sup>. Of seventeen studies examining colon cancer, five studies aimed at investigating age disparities in colon cancer survival (**Table 2**)<sup>16,17,31,32,34</sup>. Six studies used data from The Netherlands<sup>16,17,21,27,30,32</sup>, and five presented data from the U.S.A.<sup>26,31,33,34,54</sup>. The remaining studies used data from Finland<sup>53</sup>, Norway<sup>28</sup>, Germany<sup>29</sup>, Korea<sup>35,36</sup>, and Australia<sup>20</sup>. Ten studies included all cancer stages<sup>16,17,21,26,28,29,35,36,53,54</sup>, three studies restricted their analyses to stage III cancer<sup>20,27,33</sup>, and four to stages I–III<sup>30–32,34</sup>. Nine studies included all patients whatever their age at diagnosis<sup>16,17,27,28,32,34–36,53</sup>, with the inclusion criterion for age varying widely in the remaining studies. All studies analysed the age at diagnosis using age categories but the number and boundaries of these varied across studies (**Table 4**). Eight studies presented relative survival (RS) estimates<sup>16,28–30,35,36,53,54</sup> and five studies presented overall survival (OS) estimates (**Table 4**)<sup>20,21,26,27,32</sup>. The remaining studies showed 30-day postoperative mortality rates<sup>17</sup>, the cumulative incidence of death at five years<sup>31</sup>, or mortality rates<sup>33,34</sup>.

Of the twenty studies that examined lung cancer, eight studies focused on non-small cell lung cancer (NSCLC)<sup>18,44–50</sup>, three on small-cell lung cancer (SCLC)<sup>19,51,52</sup>, and nine on all lung cancer cases<sup>37–43,49,53,54</sup> (**Table 3**). Six studies aimed to evaluate age disparities in survival<sup>41,43,45,48–50</sup>. Seven studies analysed data from the Netherlands<sup>18,19,43,48–51</sup>, six from the U.S.A.<sup>37,44,47,52,54</sup>, and the remaining studies presented data from Finland<sup>53</sup>, Taiwan<sup>38,46</sup>, Korea<sup>39</sup>, the Czech Republic<sup>41</sup>, England<sup>40</sup>, and Germany<sup>42</sup>. While most studies included all stages at diagnosis, some studies restricted their sample to specific stage(s): stage I cancer<sup>45</sup>, stages I–IIIa<sup>46</sup>, stages IIIb and IV<sup>47</sup>, stage III<sup>49</sup>, and stages I or II<sup>50</sup>. Ten studies included patients of all ages at diagnosis, other studies included patients from the age of 15 (n=3)<sup>18,40,42</sup>, 18 (n=2)<sup>43,46</sup>, 20 (n=2)<sup>39,54</sup>, or 65<sup>47,49,50</sup>. All studies used age categories that differed largely across studies in terms of number and boundaries. Twelve studies presented RS estimates<sup>18,19,37,39,41,42,44,48,51,53,54</sup>, seven OS estimates<sup>38,43,46,47,49,50,54</sup>, one study net survival<sup>40</sup>, and one study presented cancer-specific survival (CSS) estimates<sup>52</sup>.

#### *Age pattern in colon and lung cancer survival*

Patterns of age disparities in survival for colon and lung cancers based on patient-related and clinical factors are shown in **Tables 4** and **5**, respectively. All numerical values extracted from included studies are shown in **Supplementary Tables 5** and **6**. While a detailed breakdown of key findings on patterns of age disparities from our review is shown in **Supplementary Material x**, we have summarised key findings below.

Regarding colon cancer survival, higher age disparities were observed in females with regional or distant cancers<sup>53</sup>, and those with left colon cancer<sup>29</sup>, while the other studies did not<sup>54</sup>. Overall, age disparities were greater as cancer spread or when the cancer stage was unknown<sup>16,26,30,53</sup>, when lymph nodes were involved<sup>28</sup>, or when fewer than 12 nodes were examined<sup>31,32</sup>. While some studies did not show different age patterns in survival based on sub-site<sup>35</sup>, others reported smaller age differences for patients with cancer of the distal colon compared to the proximal colon<sup>36,53</sup>. Regarding treatment, the presence of bias precludes accurate interpretation of studies that presented survival data across chemotherapy regimens<sup>20,27,33</sup>. One study reported postoperative mortality rates in patients who underwent an elective and non-elective resection<sup>17</sup>. It showed higher age disparities for males, those with an American Society of Anesthesiologists (ASA) score of  $\geq 3$ , those with a Charlson comorbidity score  $\geq 2$ , those with metastatic disease, and those with hemicolectomy. Complications and sepsis



after surgery<sup>34</sup>, as well as the presence of chronic obstructive pulmonary disease at the time of cancer diagnosis<sup>21</sup>, would also likely increase age disparities in colon cancer survival.

Regarding lung cancer survival, females had consistently higher age disparities in relative survival<sup>19,42,44,45,53,54</sup>. We observed no clear pattern for the role of socioeconomic level on age disparities<sup>38</sup>. Regarding the role of race/ethnicity, one study reported smaller age disparities in lung cancer survival among Black patients compared to White patients in the U.S.<sup>37</sup>. In comparison, South Asians had higher age disparities than non-South Asians in the U.K.<sup>40</sup>. Age disparities tended to decrease as the cancer spread<sup>37,39,41,44,48,50-54</sup> and were higher in patients with NSCLC than in those with SCLC<sup>53,54</sup>. One study suggested that age disparities were smaller in patients with severe comorbidities than in those without comorbidity<sup>54</sup>. Again, most studies presenting survival data by treatment group were at high risk of bias<sup>18,46,49,50,52</sup>. The only interpretable study showed that age disparities in overall survival did not differ based on the chemotherapy regimen<sup>47</sup>.

## Discussion

This review is the first to bring together the literature on those factors which influence age disparities in cancer survival, using colon and lung cancer as exemplars. While age at diagnosis is an important prognostic factor in cancer survival, very few studies, often of sub-optimal quality, have specifically focused on the relationship between age and cancer survival, and none have sought to identify patterns of age disparities in colon or lung cancer survival *per se*. However, our review showed that i) the magnitude of disparities in survival between younger and older patients differed greatly and inconsistently based on patient and clinical characteristics; ii) the stage at diagnosis was the sole clinical characteristic that consistently influenced age disparities in survival, but oppositely in colon cancer and lung cancer; and iii) age disparities in lung cancer survival were typically greater in female than in males.

While in most studies older patients had poorer survival than middle-aged patients, this was not always the case. For instance, two studies reported no age disparity in cancer survival in patients with cancer of the right colon<sup>53</sup>, and other papers showed minimal age disparities in patients with advanced lung cancer<sup>29</sup>, or small-cell lung

carcinoma<sup>53</sup>. On the other hand, age disparities were substantial in patients with distant colon cancer<sup>30,53</sup> or those with localised lung cancer<sup>37,41,44,48,53,54</sup>, particularly for patients without comorbidities<sup>54</sup>.

The influence of stage at diagnosis on age disparities differed depending on the cancer. Age disparities in colon cancer survival tended to increase with increasing stage of disease<sup>28,30</sup>, while the opposite was observed for lung cancer<sup>37,41,44,48,53,54</sup>. Surgery is the main treatment strategy for patients with colon cancer diagnosed with localised and regional stage disease, while chemotherapy is recommended for metastatic colon cancer<sup>57</sup>. It has been shown that older patients are less likely to receive chemotherapy than younger patients<sup>58-60</sup>, and less intensive therapies are usually recommended for unfit older patients<sup>61</sup>. In lung cancer, older patients with early stage disease, especially those older than 75, are less likely to undergo surgery compared to younger patients<sup>62</sup>. The high lethality of the disease, especially at a more advanced stage, may explain the small difference in survival disparities observed between middle-aged and older patients with metastatic lung cancer.

Comorbidity, the prevalence of which drastically increases with age, is an important prognostic factor in patients with cancer, because it may complicate cancer management<sup>63</sup>. However, our review identified only two studies reporting data for comorbidity, preventing us from making any conclusions regarding comorbidity and its impact on age disparities in cancer survival. One study suggested that the presence of COPD at diagnosis may increase age disparities in survival seen in patients with colon cancer<sup>21</sup>. The sole study that presented lung cancer survival data by age group and comorbidity level suggested that patients without comorbidities showed greater age disparities in survival than those with severe comorbidities<sup>54</sup>. Comorbidity alone is not enough to assess vulnerabilities in older patients with cancer, and comprehensive geriatric assessments (CGA) may be useful in capturing a more nuanced view of health, fitness and physiological aging<sup>64</sup>. Although less valuable than information derived from CGA, it is now possible in many countries to link cancer survival data to comorbidity information through linkage with administrative hospitalisation data or pharmacy data<sup>65,66</sup>, and thus further studies should describe the role of comorbidities on age disparities in survival in patients with colon or lung cancer.

Unfortunately, we are unable to draw any conclusions regarding the role of treatment on age disparities in colon and lung cancer survival. Indeed, most studies presenting survival data by treatment group were at high risk of immortal time bias<sup>27,33,49,50,52</sup>. Immortal time bias occurs when survival comparisons are made between groups of patients based on a factor (e.g. treatment) that is defined after the start of the follow-up (e.g. cancer diagnosis

date). Patients in the treated group survived long enough to be treated, while others in the untreated group may have died before having that chance. As a consequence, the treatment may be erroneously considered as effective because patients in the treated group have, on average, a better survival than those in the untreated group. In reality, the apparent better survival in the treated group may be the result of the selection of the fittest patients (*i.e.* those who had the better chance to survive). For instance, this bias may be at play in the 2010 study of van Steenberg et al. and would explain the higher survival amongst the oldest age group in the 'no chemotherapy' group<sup>27</sup>, or in the study of Sigel et al. that reported higher 2-year RS in female patients older than 80 years compared to those younger than 60<sup>45</sup>. With a few exceptions<sup>34,40,47,53,54</sup>, the overall quality of studies included in this review was poor. Further high quality studies are required if we are to better identify the role of treatment as a possible driver of age disparities in cancer survival.

Only a few studies provide information about patient characteristics. The sole patient characteristic examined in the colon cancer studies was sex, and the results were inconsistent<sup>29,53,54</sup>. However, the included lung cancer studies suggested that the difference in 5-year survival between younger and older patients is wider in females than in males<sup>19,37,42,53</sup> but this was not necessarily the case for 1 and 3-year survival<sup>19</sup>. In the study by Dickman et al., females aged 45-59 years old had better 1-year RS than males of the same age; however, females aged 75 years or older had lower 1-year RS than their male counterparts<sup>53</sup>. Even if some evidence suggests a positive effect of sex hormones on survival from NSCLC in females<sup>67</sup>, the implication of sex hormones is still not clear<sup>68</sup>. However, because of the observational nature of the studies included, survival bias may also be an explanation for the difference observed across sexes. In terms of race/ethnicity, age disparities in lung cancer survival seem to be influenced by race/ethnicity in the U.S and the UK, but results are inconsistent<sup>37,40</sup>, probably because of differences between health-care systems, or possible survival bias. Finally, the role of socioeconomic level in age disparities in lung cancer survival is not clear<sup>38</sup>. While sex, ethnicity/race and socioeconomic level are known to influence cancer survival<sup>69-71</sup>, their role in age disparities in cancer survival remain unclear and should be further explored.

Many other characteristics may be important in explaining lower survival amongst older patients. When using observational data, data related to demographics and cancer are the easiest to study. However, other factors

such as those related to the health-care system (e.g. physical and financial access to cancer facilities) are likely to be more difficult to measure, and therefore were less likely to be included in this review.

Older adults have a higher risk of dying from causes other than cancer than younger adults. While of interest for patients and clinicians<sup>72</sup>, OS measures are of limited value when studying disparities in survival between younger and older patients, mainly because they do not make a distinction between the causes of death, and because of the higher risk of background mortality in older patients. Identifying the underlying cause of death may be challenging in older adults who may present with co-existing serious disease, making cancer-specific survival difficult to estimate. When studying the age disparities in survival, it is therefore crucial to take into account this difference in background mortality. Accordingly, relative survival (*i.e.* the ratio of the observed survival among patients with cancer over the [expected] survival among the general population obtained from national life tables) or net survival (*i.e.* the probability of being alive after a defined period of time in the hypothetical world where one can die only from cancer) are suited to this purpose. However, lifetables used to estimate the expected survival should be adequately stratified by likely important factors (e.g. comorbidity, smoking status)<sup>73</sup>.

Our systematic review has limitations. We could not conduct any quantitative analysis (such as meta-analysis) because of the vast heterogeneity of studies included, which prevented us from quantifying the relationship between increasing age and cancer survival. This is largely a reflection of the quality of the studies included in this review. We did, however, attempt to synthesise the available evidence into the key findings, as discussed above.

With the rapidly increasing number of older patients with cancer<sup>14</sup>, there is a dire need for a better understanding of the drivers of the disparities in colon and lung cancer survival between older and younger patients, ultimately enhancing the probability of patients surviving their cancer regardless of their age. While it is not realistic to believe that survival amongst older adults can equal that of middle-aged adults, there is more that can be done to minimise age disparities in colon and lung cancer survival – but the current quality of evidence prevents a full understanding of the key drivers of these disparities.

## **Conclusion**

In this systematic review, we have investigated age disparities in cancer survival using colon and lung cancer – two differing cancer contexts in terms of the likely impact of age on survival – as exemplars. The present review highlights both the lack of knowledge about age disparities in colon and lung cancer survival, and the absence of geriatric variables (e.g. cognition, functional status, social support, nutritional status, etc.) investigated within current population-based research. With the growth of the use of administrative health data in several (high income) countries and an increased emphasis being placed on data quality, we can expect a more accurate description of age disparities in colon and lung cancer survival in the near future and a subsequent improved understanding of what drives them.

### **Author contributions**

SP designed the study, wrote the protocol, screened all titles, abstracts and full-texts, and drafted the manuscript. HG screened 10% of abstracts and full-texts, extracted data from included papers, and critically reviewed the manuscript.

VS reviewed the protocol, screened 10% of titles and critically reviewed the manuscript.

JG critically reviewed the protocol and the manuscript.

MJH helped with the interpretation and critically reviewed the manuscript.

RC supervised the study, helped with the interpretation and critically reviewed the manuscript.

DS helped with the interpretation and critically reviewed the manuscript.

Data statement

Not applicable.

### **Declaration of competing interest**

None

### **Funding**

Sophie Pilleron has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 842817.

## Tables list

Table 1 Quality assessment of included studies

Table 2 Characteristics of included studies about colon cancer

Table 3 Characteristics of included studies about lung cancer

Table 4 Data extraction of included studies about age disparities in colon cancer survival

Table 5 Data extraction of included studies about age disparities in lung cancer survival

**Table 1. Quality assessment of included studies**

First author, date	Cancer site	Article's source	1 - Selection bias				2- Pronostic factor measurement		3- Outcome measurement	4 - Statistical reporting			
			Inclusion criteria	Exclusion criteria	Time zero appropriately defined	Baseline characteristics adequately described	Source of age mentioned	Definition of factors studied	Source of mortality data mentioned	End of follow-up reported	Summary of follow-up given	Number of deaths given	Numerical estimate of survival by age groups in each group of comparison are given
<b>Criteria</b>			Defined: Criteria mentioned Not defined: no criteria mentioned		Defined and appropriate: time zero clearly mentioned and appropriately defined Defined and not appropriate: Time zero clearly mentioned but not adapted to the analysis (i.e. factors of interest collected after time zero) Not defined: time zero not clearly mentioned	Yes: Described by age group Partially: Sample described but not by age groups No: No description	Yes: The original source is reported No: Not reported	Yes: Reported Partially: Not fully defined (i.e. the data source is not described) No: Not reported	Yes: The original source is reported Partially: Not specific enough No: Not reported	Yes: Reported Partially: Not specific enough No: Not reported	Yes: Reported No: Not reported		
Dickman et al., 1999 <sup>53</sup>	Both sites	References' list	Defined	Defined	Defined and appropriate	Yes	No	Partially	Yes	Yes	No	No	Yes
Mariotto et al., 2014 <sup>54</sup>	Both sites	Known by SP	Not defined	Not defined	Defined and appropriate	Partially	No	No	No	Yes	No	No	Yes
Yancik et al., 1998 <sup>26</sup>	Colon	Databases	Defined	Not defined	Not defined	Partially	No	Yes	Yes	Yes	No	Yes	No
van de Schans et al., 2007 <sup>21</sup>	Colon	Databases	Defined	Not defined	Defined and appropriate	Yes	No	Yes	Yes	Yes	No	No	No
van Steenberg et al., 2010 <sup>27</sup>	Colon	Databases	Defined	Not defined	Defined but not appropriate	Yes	Yes	No	Yes	Yes	No	No	Yes

First author, date	Cancer site	Article's source	1 - Selection bias				2- Pronostic factor measurement		3- Outcome measurement	4 - Statistical reporting			
			Inclusion criteria	Exclusion criteria	Time zero appropriately defined	Baseline characteristics adequately described	Source of age mentioned	Definition of factors studied	Source of mortality data mentioned	End of follow-up reported	Summary of follow-up given	Number of deaths given	Numerical estimate of survival by age groups in each group of comparison are given
Nedrebø et al., 2011 <sup>28</sup>	Colon	Databases	Defined	Defined	Not defined	Partially	No	Yes	Yes	Yes	No	No	Yes
van den Broek et al., 2011 <sup>16</sup>	Colon	Databases	Defined	Not defined	Not defined	Yes	No	Partially	Yes	Yes	No	No	No
Kolfschoten et al., 2012 <sup>17</sup>	Colon	Databases	Defined	Defined	Defined and appropriate	Partially	No	Yes	Yes	Yes	No	Yes	No
Majek et al., 2013 <sup>29</sup>	Colon	Databases	Defined	Defined	Not defined	Partially	No	Yes	No	No	No	No	Yes
Park et al., 2013 <sup>36</sup>	Colon	Databases	Defined	Not defined	Not defined	No	No	Yes	No	No	No	No	Yes
Van Steenberghe et al., 2013 <sup>30</sup>	Colon	Databases	Defined	Defined	Not defined	Partially	Yes	Yes	Yes	Yes	No	No	Yes
Khan et al., 2014 <sup>31</sup>	Colon	Databases	Defined	Defined	Not defined	Yes	No	Yes	No	Yes	No	No	Yes
Aan De Stegge et al., 2016 <sup>32</sup>	Colon	Databases	Defined	Defined	Not defined	Partially	No	Yes	Yes	Yes	Yes	No	Yes
Hines et al., 2016 <sup>33</sup>	Colon	Databases	Defined	Defined	Defined but not appropriate	Yes	No	Yes	No	Yes	Yes	Yes	Yes
Aquina et al., 2017 <sup>34</sup>	Colon	Databases	Defined	Defined	Defined and appropriate	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes
Brungs et al., 2018 <sup>20</sup>	Colon	Databases	Defined	Defined	Not defined	Yes	No	Partially	Yes	Yes	No	No	Yes
Hur et al., 2018 <sup>35</sup>	Colon	Databases	Defined	Not defined	Not defined	Yes	No	Yes	No	No	No	No	Yes



First author, date	Cancer site	Article's source	1 - Selection bias				2- Pronostic factor measurement		3- Outcome measurement	4 - Statistical reporting			
			Inclusion criteria	Exclusion criteria	Time zero appropriately defined	Baseline characteristics adequately described	Source of age mentioned	Definition of factors studied	Source of mortality data mentioned	End of follow-up reported	Summary of follow-up given	Number of deaths given	Numerical estimate of survival by age groups in each group of comparison are given
Ries et al., 1994 <sup>44</sup>	Lung	Databases	Defined	Defined	Defined and appropriate	Partially	Yes	Yes	No	No	No	No	Yes
Wingo et al., 1998	Lung	Databases	Defined	Not defined	Not defined	No	No	Yes	Yes	Yes	No	No	Yes
Janssen-Heijnen et al., 1998 <sup>51</sup>	Lung	Databases	Defined	Defined	Not defined	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes
Sigel et al., 2009 <sup>45</sup>	Lung	References' list	Defined	Not defined	Defined but not appropriate	Yes	No	Yes	Yes	Yes	No	No	Yes
Chang et al., 2012 <sup>38</sup>	Lung	Databases	Defined	Not defined	Defined and appropriate	Yes	No	Yes	Partially	Partially	No	No	Yes
Janssen-Heijnen et al., 2012 <sup>19</sup>	Lung	Databases	Defined	Defined	Defined and appropriate	Partially	No	Yes	Yes	Yes	No	No	No
Lin et al., 2012 <sup>46</sup>	Lung	Databases	Defined	Defined	Defined but not appropriate	Yes	No	Yes	Yes	Yes	No	Yes	No
van der Drift et al., 2012 <sup>18</sup>	Lung	Databases	Defined	Defined	Defined but not appropriate	Yes	No	Yes	Yes	Yes	No	No	No
Jung et al., 2013 <sup>39</sup>	Lung	Databases	Defined	Defined	Defined and appropriate	Yes	No	Yes	Yes	Yes	No	No	Yes
Langer et al., 2014 <sup>47</sup>	Lung	Databases	Defined	Defined	Defined and appropriate	Yes	No	Yes	No	Yes	Yes	Yes	Yes
Eberle et al., 2015 <sup>42</sup>	Lung	Databases	Defined	Defined	Defined and appropriate	Yes	No	Yes	No	Yes	No	Yes	Yes
Maringe et al., 2015 <sup>40</sup>	Lung	Known by SP	Defined	Defined	Defined and appropriate	Yes	No	Yes	Yes	Yes	No	No	Yes
Petera et al., 2015 <sup>41</sup>	Lung	Databases	Not defined	Not defined	Not defined	Partially	No	Yes	Yes	No	No	No	Yes

First author, date	Cancer site	Article's source	1 - Selection bias				2- Pronostic factor measurement		3- Outcome measurement	4 - Statistical reporting			
			Inclusion criteria	Exclusion criteria	Time zero appropriately defined	Baseline characteristics adequately described	Source of age mentioned	Definition of factors studied	Source of mortality data mentioned	End of follow-up reported	Summary of follow-up given	Number of deaths given	Numerical estimate of survival by age groups in each group of comparison are given
Driessen et al., 2017 <sup>48</sup>	Lung	Databases	Defined	Defined	Defined and appropriate	Yes	No	Yes	Yes	Yes	No	No	Yes
Schulkes et al., 2017 <sup>43</sup>	Lung	Databases	Defined	Defined	Not defined	Yes	No	Yes	Yes	Yes	No	No	Yes
Wang et al., 2017 <sup>52</sup>	Lung	Databases	Defined	Defined	Not defined	Yes	No	No	No	No	No	No	Yes
Driessen et al., 2018 <sup>49</sup>	Lung	Databases	Defined	Defined	Defined but not appropriate	Yes	No	Yes	Yes	Yes	Yes	No	Yes
Driessen et al., 2019 <sup>50</sup>	Lung	Databases	Defined	Defined	Defined but not appropriate	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes

**Table 2 Characteristics of included studies about colon cancers**

First author, date	Location of data	Objective	Definition of cancer	Stage at diagnosis	Age at diagnosis	Exclusion criteria	Period of cancer diagnosis	Source of cancer data	Source of mortality data
--------------------	------------------	-----------	----------------------	--------------------	------------------	--------------------	----------------------------	-----------------------	--------------------------

First author, date	Location of data	Objective	Definition of cancer	Stage at diagnosis	Age at diagnosis	Exclusion criteria	Period of cancer diagnosis	Source of cancer data	Source of mortality data
Yancik et al., 1998 <sup>26</sup>	U.S.A.	"... we document the comorbidity in older colon carcinoma patients and evaluate the influence of various diseases on cancer survival. We focus on the role of comorbidity in early mortality. Guiding research questions were: 1) What is the comorbidity burden of older colon carcinoma patients? 2) Does the comorbidity burden of colon carcinoma patients correlate with their disease stage? and 3) Does the comorbidity burden contribute to early mortality of the patient?"	Colon carcinoma	All stages	≥ 55	Not mentioned	1992	SEER	Active follow-up method of the NCI SEER Program.
Dickman et al., 1999 <sup>53</sup>	Finland	"In the current publication we provide information on trends in survival for patients diagnosed from 1955–1994, along with a detailed description of survival for patients diagnosed in the period 1985–1994."	Carcinoma of the colon Carcinoid tumour of the colon	All stages	Not mentioned	Carcinoma in situ lesions Death certificate only Diagnosis at autopsy	1985–1994	Finnish Cancer Registry	National population register
van de Schans et al., 2007 <sup>21</sup>	Eindhoven, the Netherlands	"...investigated the prevalence of COPD among newly diagnosed cancer patients. Furthermore, we assessed whether such patients had a different stage at diagnosis, were treated differently, and to what extent they had a different outcome compared to newly	all new colon cancer cases	All stages	≥ 35	Not mentioned	1995-2004	Eindhoven Cancer Registry	Passive follow-up via hospitals + active follow-up from the municipal personal records database

First author, date	Location of data	Objective	Definition of cancer	Stage at diagnosis	Age at diagnosis	Exclusion criteria	Period of cancer diagnosis	Source of cancer data	Source of mortality data
		diagnosed cancer patients without COPD."							
van Steenberg et al., 2010 <sup>27</sup>	the Netherlands	"In order to evaluate adherence to these guidelines in southern Netherlands in recent years, we assessed factors associated with the administration of chemotherapy. Variation between hospitals was assessed to differentiate between early and late adapters for adjuvant chemotherapy administration. In addition, we determined to what extent these factors and the introduction of new chemo-therapeutic agents were related to survival at a population-based level."	Primary colon cancer (C18.0–C18.7)	Stage III	Not mentioned	None	2001-2007	Eindhoven Cancer Registry	Passive follow-up via the hospitals and active follow-up from civil municipal registries and the Central Bureau for Genealogy
van den Broek et al., 2011 <sup>16</sup>	the Netherlands	"... the aim of our study was to describe treatments and compare survival rates over time between middle-aged (<65 years), aged (65-74years) and elderly (≥ 75 years) colon cancer patients."	First primary invasive colon cancer (C18.0)	All stages	Not mentioned	None	1991-2005	Comprehensive Cancer Centre West	CCCW established vital status either directly from the patients' medical record or through linkage of cancer registry data with the municipal population registries which

First author, date	Location of data	Objective	Definition of cancer	Stage at diagnosis	Age at diagnosis	Exclusion criteria	Period of cancer diagnosis	Source of cancer data	Source of mortality data
									record information on their inhabitants' vital status.
Nedrebø et al., 2011 <sup>28</sup>	Norway	"The aim of this study was to investigate how changes in national strategies for surgical treatment have influenced survival from colonic and rectal cancer in a national cohort."	Adenocarcinoma of the colon  (assumed to have undergone a curative resection)	All stages	Not mentioned	Tumours other than adenocarcinomas In situ cancers Distant metastases Treatment with non-resective procedures	1993-2004	Cancer Registry of Norway	Statistics Norway
Kolfschoten et al., 2012 <sup>17</sup>	the Netherlands	"... to assess which factors contribute to poor postoperative outcome, especially in elderly patients who undergo emergency colon cancer resections..."	Colon carcinoma	Not mentioned	Not mentioned	Patients treated for a rectum carcinoma Patients treated for a recurrent disease or multiple synchronous colorectal tumors Records that did not contain information about the tumor location, the date of surgery, urgency of the procedure, or hospital survival	January 1-December 31, 2010 (date of surgery)	Dutch Surgical Colorectal Audit	Not mentioned
Majek et al., 2013 <sup>29</sup>	Germany	"...to compare survival from CRC between men and women and to explore potential reasons for sex differences in a large	Primary invasive colon cancer	All stages	≥ 15	Death certificate only Unknown years of birth/death	1997-2006	German cancer registries	Not mentioned

First author, date	Location of data	Objective	Definition of cancer	Stage at diagnosis	Age at diagnosis	Exclusion criteria	Period of cancer diagnosis	Source of cancer data	Source of mortality data
		population-based cancer survival study from Germany."							
Park et al., 2013 <sup>36</sup>	Korea	"... to use the KCCR data to evaluate the characteristics of Korean CRC, focusing on the variation in survival according to a specific age group, sex, or tumor location."	Colon cancer (C18.0-18.7)	All stages	Not mentioned	Not mentioned	1993-2010	Korea Central Cancer Registry	Not mentioned
Van Steenberg et al., 2013 <sup>30</sup>	the Netherlands	"... we determined conditional 5-year relative survival rates for colon cancer patients, according to age, gender and tumour stage for each additional year survived up to 15 years after diagnosis."	Invasive primary colon cancer (C18.0-C18.9)	Stages I-III	15-89	Diagnosis at autopsy Sarcomas and lymphomas	1989-2008	Netherlands Cancer Registry	Passive follow-up via the hospitals and date of death retrieved from the Municipal Personal Records Database for deaths occurring since October 1994; for patients diagnosed before October 1994, follow-up completed by merging with municipality death records or with the Central Bureau for Genealogy
Khan et al., 2014 <sup>31</sup>	U.S.A.	"... to compare the frequency of nodal involvement in resectable colon cancer between younger and older patients and evaluate if the survival benefits of adequate lymph node retrieval differ between the age groups."	Adenocarcinoma of the colon	Stages I-III	≥ 20	Carcinoid and neuroendocrine carcinomas Death certificate only Diagnosis at autopsy Unrecorded stage	2000-2010	SEER	Not mentioned

First author, date	Location of data	Objective	Definition of cancer	Stage at diagnosis	Age at diagnosis	Exclusion criteria	Period of cancer diagnosis	Source of cancer data	Source of mortality data
						Unclear if colon or rectum			
Mariotto et al., 2014 <sup>54</sup>	U.S.A.	"... to describe the different survival measures, the methods and assumptions behind them and their respective interpretation in less technical language. The second is to provide a presentation template for summarizing cancer survival statistics for major cancer sites,..."	Lung cancer	Lung and Bronchus cancer	All stages	20+	Not mentioned	2004-2009	SEER 18 registries
Aan De Stegge et al., 2016 <sup>32</sup>	the Netherlands	"... to investigate whether the removal of more ( $\geq 12$ ) lymph nodes can explain differences in survival rates between elderly and younger patients diagnosed with colon cancer."	Adenocarcinoma of the colon	Stages I-III	Not mentioned	Unknown tumour location Unknown number of removed lymph nodes Unknown lymph nodal status No correspondence between TNM classification and lymph nodal status Receipt of neo-adjuvant treatment	2003-2010	Netherlands Cancer Registry	Linkage with the municipality register
Hines et al., 2016 <sup>33</sup>	Georgia, the U.S	"...1) to assess the proportion of stage III CC patients who received ACT overall and by age, 2) to evaluate the absolute and relative survival benefit of receiving ACT	Adenocarcinoma of the colon	Stage III	40-84	No surgery within 90 days of diagnosis Unknown surgical status Death within 6	2000-2007	Georgia Comprehensive Cancer Registry	Not mentioned

First author, date	Location of data	Objective	Definition of cancer	Stage at diagnosis	Age at diagnosis	Exclusion criteria	Period of cancer diagnosis	Source of cancer data	Source of mortality data
		following surgery for stage III CC patients overall and according to age, and 3) to evaluate whether propensity score methodology afforded additional control over confounding variables by comparing estimates obtained via multivariable modeling (MM), propensity score weighting (PSW), and propensity score matching (PSM)."				months of diagnosis Not receiving adjuvant chemotherapy due to contraindications Multiple primary tumors Race other than black/white Missing census tract code Unknown chemotherapy status			
Aquina et al., 2017 <sup>34</sup>	New York State, U.S.A.	"... to examine age-related differences in postoperative complications, 1-year survival, and cause-specific mortality among patients in New York State using a linked population-based dataset between the state cancer registry and state hospital discharge database."	Patients who underwent colectomy for stage I-III colon adenocarcinoma	Stages I-III	Not mentioned	Missing data related to adjuvant therapy, the unique surgeon identifier, surgeon board-certification status, surgeon year of training completion, or TNM staging or if they died within 30 days of surgery.	2004-2011	New York State Cancer Registry	Linkage to vital records and the National Death Index to provide the cause and date of death for patients
Brungs et al., 2018 <sup>20</sup>	Australia	"... to investigate the comparative effectiveness of the addition of oxaliplatin to fluoropyrimidine monotherapy as adjuvant treatment for stage III colon cancer in a "real world population" of patients older than 70 years."	Colon adenocarcinoma	Stage III	≥ 18	Death within 30 days of surgery Delay starting chemotherapy past 120 days	2006-2009 2010-2013	New South Wales clinical cancer registry	Linkage to the NSW registry of Births, Deaths, and Marriages by the Centre for Health Record Linkage.



First author, date	Location of data	Objective	Definition of cancer	Stage at diagnosis	Age at diagnosis	Exclusion criteria	Period of cancer diagnosis	Source of cancer data	Source of mortality data
Hur et al., 2018 <sup>35</sup>	Korea	"The purpose of this study was to investigate the characteristics of Korean patients with CRC, focusing on survival outcomes across tumor distribution, stage, and patient sex and age by using data from a nationwide cancer registry."	Pathologically-identified adenocarcinomas of the colon	All stages	Not mentioned	Not mentioned	1996-2015	Korea Central Cancer Registry	Not mentioned

Table 3 Characteristics of included studies about lung cancer

First author, date	Location of data	Objective	Definition of cancer	Stage at diagnosis	Age at diagnosis	Exclusion criteria	Period of cancer diagnosis	Source of cancer data	Source of mortality data
<b>Lung cancer</b>									
Wingo et al., 1998 <sup>37</sup>	U.S.A.	"...to study gender, race, age, and stage-specific relative survival at 5,10, and 15 years after diagnosis of cancer of the breast, prostate, colon and rectum, and lung."	First primary diagnosis of lung cancer	All stages	Not mentioned	Not mentioned	1974-1991	SEER	Active follow-up: match cases annually with deaths recorded in the corresponding states and with the National Death Index + other methods if appropriate
Dickman et al., 1999 <sup>53</sup>	Finland	"In the current publication we provide information on trends in survival for patients diagnosed from 1955–1994, along with a detailed description of survival for patients diagnosed in the period 1985–1994."	Carcinoma of the lung Cancers of the trachea and carcinoid tumours of the bronchus	All stages	Not mentioned	Carcinoma in situ lesions Death certificate only Diagnosis at autopsy Cancers of the pleura	1985–1994	Finnish Cancer Registry	National population register
Chang et al., 2012 <sup>38</sup>	Taiwan	"This article describes and compares the overall survival rates and relative risk of death in patients diagnosed with their first malignant tumor in 2002."	Patients with incidental lung cancer who <b>began treatment</b> in 2002.	All stages	Not mentioned	Not mentioned	2002	Taiwan National Health Insurance Research Database	Linkage to the mortality data. Each patient was tracked from his or her first curative treatment for a five-year period using administrative data to identify all patients who died during the study period.

First author, date	Location of data	Objective	Definition of cancer	Stage at diagnosis	Age at diagnosis	Exclusion criteria	Period of cancer diagnosis	Source of cancer data	Source of mortality data
Jung et al., 2013 <sup>39</sup>	Korea	"This study aimed at reporting the stage-specific survival rates for the 8 most common cancers diagnosed during the period 2006-2010 in Korea and at comparing the stage-specific survival rates between Korea and the US."	Primary lung cancer (C33-C34)	All stages	≥ 20	Death Certificate Only Unknown years of birth/death	2006-2010	Korea Central Cancer Registry	Passive follow-up using mortality database maintained from the Statistics Korea and population registration database from the Ministry of Security and Public Administration
Mariotto et al., 2014 <sup>54</sup>	U.S.A.	"... to describe the different survival measures, the methods and assumptions behind them and their respective interpretation in less technical language. The second is to provide a presentation template for summarizing cancer survival statistics for major cancer sites,..."	Lung and Bronchus cancer	All stages	20+	Not mentioned	2004-2009	SEER 18 registries	Not mentioned

First author, date	Location of data	Objective	Definition of cancer	Stage at diagnosis	Age at diagnosis	Exclusion criteria	Period of cancer diagnosis	Source of cancer data	Source of mortality data
Maringe et al., 2015 <sup>40</sup>	England	"... to determine how cancer survival in the South Asian population of England has changed between 1986 and 2004, how it varies by age and deprivation, and how these patterns compare with those observed in non-South Asians. "	Invasive, primary lung cancer (C33, C34)	All stages	15-69	Vital status unknown DCO No information on the postcode of residence	1986-2004	National Cancer Registry	Office for National Statistics
Petera et al., 2015 <sup>41</sup>	the Czech Republic	"... to evaluate cancer epidemiology in the Czech Republic from the years 2006 to 2010 and to assess differences in treatment and outcomes between elderly and non-elderly patients. "	Not mentioned	All stages	Not mentioned	Not mentioned	2006–2010	Czech National Cancer Registry	Not mentioned
Eberle et al., 2015 <sup>42</sup>	Germany	"The aim of this investigation is the identification of factors which affect the relatively high survival rates for lung cancer in Germany. "	Primary invasive lung cancer (ICD-10: C33-34)	All stages	≥15	Death Certificate Only	2007-2010	12 cancer registries in Germany	Not mentioned

First author, date	Location of data	Objective	Definition of cancer	Stage at diagnosis	Age at diagnosis	Exclusion criteria	Period of cancer diagnosis	Source of cancer data	Source of mortality data
Schulkes et al., 2017 <sup>43</sup>	the Netherlands	"... we analyzed patient data on lung cancer from a nationwide registry in the Netherlands, regarding diagnostic work-up, treatment choices, and survival in different age categories: the oldest old ( $\geq 85$ years of age), the elderly (71–84 years), and younger patients (18–70 years)."	Patients with non-small cell lung cancer or small cell lung cancer	All stages	$\geq 18$	Impossible to categorize treatment due to lack of information.	2010-2014	Netherlands Cancer Registry	Linkage of the Cancer Registry data with municipal population registries
<b>Non-small cell lung cancer</b>									
Ries et al., 1994 <sup>44</sup>	U.S.A.	"... a comprehensive analysis of the influence of extent of disease, histologic type, histologic grade, and demographic factors on lung cancer survival."	Histologically confirmed cases of invasive lung cancer	All stages	Not mentioned	Not the first primary cancer Diagnosis at autopsy Death certificate only, In situ cancers Unknown or other race Unknown survival time	1983-1987	SEER	Not mentioned
Sigel et al., 2009 <sup>45</sup>	U.S.A.	"In this study, we used national data from the SEER database to compare relative survival rates of patients with resected and unresected stage I non-small-cell lung cancer (NSCLC) according to age to evaluate the impact of	Primary cancer (tumor site codes 34.0–34.9 and ICD-O-2 morphology codes 8010–8040, 8050–8076, 8140, 8143, 8250–8260, 8310, 8320, 8323, 8470–8490, 8550–8573), diagnosed prior to autopsy	Stage I	No restriction	Not mentioned	1995-2004	SEER	State death certificates

First author, date	Location of data	Objective	Definition of cancer	Stage at diagnosis	Age at diagnosis	Exclusion criteria	Period of cancer diagnosis	Source of cancer data	Source of mortality data
		competing causes of death on the outcomes of elderly patients."							
Lin et al., 2012 <sup>46</sup>	Taiwan	"... we conducted this retrospective population-based analysis of the Taiwan Cancer Registry (TCR) database to examine the survival benefit of adjuvant chemotherapy for Asian patients with stage I-IIIa NSCLC."	Histologically proven (International Classification of Disease for Oncology codes 339-349 and morphology codes 8010, 8012-8013, 8022, 8032-8033, 8046, 8050, 8052, 8070-8072, 8082-8083, 8140, 8200, 8211, 8230, 8240, 8246, 8249-8250, 8252-8255, 8260, 8310, 8320, 8323, 8333, 8430, 8480-8481, 8490, 8550, 8560, 8711, 8890 and 8972) who received a curative operation with a clear surgical margin.	I-IIIa	≥18	All cases with second primary malignancies and those receiving anticancer treatment prior to surgery	2004-2007	Taiwan Cancer Registry	Linkage with the database of death registry
van der Drift et al., 2012 <sup>18</sup>	the Netherlands	"... to examine changes in treatment and survival of NSCLC patients in the Netherlands in the last 20 years, on a	Microscopically verified cancer (C34, ICD-O morphology codes 8010-14, 8020-22, 8030-33, 8046, 8050-78, 8082-84, 8090,	All stages	15-95	Diagnosis at autopsy	1989-2009	Netherlands Cancer Registry	Initially obtained from municipal registries and hospitals and from 1995 onward from the nationwide population registries network.

First author, date	Location of data	Objective	Definition of cancer	Stage at diagnosis	Age at diagnosis	Exclusion criteria	Period of cancer diagnosis	Source of cancer data	Source of mortality data
		population-based level, according to stage, age group, and sex."	8094, 8123, 8140-41, 8190, 8200, 8211, 8230-31, 8250-63, 8290, 8310, 8323, 8333, 8430, 8470-90, 8550-51, 8560, 8562, 8570-75, 8972, 8980-82)						
Langer et al., 2014 <sup>47</sup>	U.S.A.	"In late 2012, a larger SEER-Medicare dataset with a greater duration of follow-up was released by the National Cancer Institute (NCI), warranting a re-analysis of the impact of combining bevacizumab with CP versus CP alone on OS in elderly patients with advanced non squamous NSCLC diagnosed through 2009. As secondary objective, hospitalization rates and durations of hospital stays were also analyzed."	Advanced non-squamous NSCLC	Stages IIIB and IV	≥65	Deaths within 30 days of the initial diagnosis No histologically confirmation If the cancer was not the first and only cancer; Other treatment than bevacizumab, carboplatin or paclitaxel within one month of the index date. Incomplete medical records in the SEER-Medicare database.	2006-2009	SEER	SEER

First author, date	Location of data	Objective	Definition of cancer	Stage at diagnosis	Age at diagnosis	Exclusion criteria	Period of cancer diagnosis	Source of cancer data	Source of mortality data
Driessen et al., 2017 <sup>48</sup>	the Netherlands	"This study focuses on describing trends and disparities over time in treatment, relative survival (RS), and the contribution of treatment toward changes in relative excess risk of mortality (RER) between younger and older patients with CLC over the last 25 years in the Netherlands, according to patient and tumor characteristics."	Primary invasive lung cancer (ICD-O: C34; 8010-8020, 8022-8035, 8046-8230, 8243-8246, 8250-8576, 8972, 8980-8982 and 9110)	All stages	Not mentioned	Patients with small cell lung cancer, carcinoid tumors, absence of pathological verification, or incidental diagnosis at autopsy	1990-2014	Netherlands Cancer Registry	from municipal registries and hospitals and since 1995 from the nationwide population registries network
Driessen et al., 2018 <sup>49</sup>	the Netherlands	To describe unselected patients with stage III NSCLC aged 65–74 years and those aged ≥75 years regarding patterns of treatment and survival in relation with patient and tumour characteristics in the Netherlands.	Non-small cell lung cancer	Stage III	≥65	Diagnoses of other histologies No pathological verification Diagnosis at autopsy	2009–2013	Netherlands Cancer Registry	Nationwide population registries network



First author, date	Location of data	Objective	Definition of cancer	Stage at diagnosis	Age at diagnosis	Exclusion criteria	Period of cancer diagnosis	Source of cancer data	Source of mortality data
Driessen et al., 2019 <sup>50</sup>	the Netherlands	"... our study compares treatment patterns and overall survival (OS) for patients aged 65–74 years and those aged ≥75 years with clinical stage I and II NSCLC in daily clinical practice in the Netherlands."	Clinical stage I or II NSCLC	Stage I-II	≥65	Patients with other histologies Diagnosis at autopsy External radiotherapy with sensitizer, targeted therapy, other treatment, or unknown treatment	2010-2015	Netherlands Cancer Registry	Nationwide population registries network
<b>Small cell lung cancer</b>									
Janssen-Heijnen et al., 1998 <sup>51</sup>	Eindhoven, the Netherlands	"We studied treatment policy for and both short-term and long-term survival of unselected patients with SCLC diagnosed in south-eastern Netherlands since 1975, the period of development of cytotoxic therapy."	Small cell lung cancer	All stages	Not mentioned	Diagnosis at autopsy; Died within the first month of diagnosis	1990-1992	Eindhoven Cancer Registry	Active follow-up
Janssen-Heijnen et al., 2012 <sup>19</sup>	the Netherlands	"This article focuses on the trends in incidence of SCLC, treatment strategies, and survival of unselected patients with SCLC in the Netherlands since 1989."	Primary cancer (C34.0-C34.9 and morphology codes 8041–8045)	All stages	Not mentioned	<15 years old and >95 years old; Diagnosis at autopsy	1989-2009	Netherlands Cancer Registry	Active follow-up, obtained from the municipal registries and from the database of deceased persons of the Central Bureau for Genealogy.

First author, date	Location of data	Objective	Definition of cancer	Stage at diagnosis	Age at diagnosis	Exclusion criteria	Period of cancer diagnosis	Source of cancer data	Source of mortality data
Wang et al., 2017 <sup>52</sup>	U.S.A.	"... to determine the prognostic value of age on patients with SCLC."	Pathologically confirmed cancer Confirmed age, active follow-up and only one primary tumor.	All stages	Not mentioned	Incomplete staging Unknown age Unknown cause of death Unknown survival months Died within 30 days after surgery	2010-2013	SEER	Not mentioned

Table 4 Data extraction of included studies about age disparities in colon cancer survival

First author, date	Age categories	Sampling	Time zero	End of follow-up	Survival metrics	Method	Sample size	Factors and its definition
Yancik et al., 1998 <sup>26</sup>	55-64; 65-74; ≥75	Age-stratified random sample by gender	Not clearly mentioned.	December 31, 1993	OS	Kaplan-Meier	1,610	<p><u>Stage: TNM classification</u></p> <p>No numerical estimates available from the paper or the author.</p> <p><i>One year after the cancer diagnosis, the age difference in survival was the biggest for patients with unknown stage cancer. The age difference was similar across patients with cancer of stages I, II or IV; however, the age difference in survival was important for patients with stage III cancer.</i></p>

First author, date	Age categories	Sampling	Time zero	End of follow-up	Survival metrics	Method	Sample size	Factors and its definition																																																																																											
Dickman et al., 1999 <sup>53</sup>	30-44; 45-59; 60-74; ≥75	None	Cancer diagnosis	December 31, 1995	1,5-year RS	Hakulinen	Not mentioned	<p>Sub-sites: caecum &amp; ascending; Transverse; Descending &amp; Sigmoid; Other</p> <table border="1"> <thead> <tr> <th rowspan="2">Subsite</th> <th colspan="2">5-year RS (95% CI)</th> <th rowspan="2">Abs. diff.</th> </tr> <tr> <th>45-59 years old</th> <th>≥75 years old</th> </tr> </thead> <tbody> <tr> <td>Caecum &amp; Ascending</td> <td>53 (48–59)</td> <td>52 (47–56)</td> <td>1</td> </tr> <tr> <td>Transverse</td> <td>47 (40–54)</td> <td>38 (32–45)</td> <td>9</td> </tr> <tr> <td>Descending &amp; Sigmoid</td> <td>54 (49–59)</td> <td>48 (43–52)</td> <td>6</td> </tr> <tr> <td>Other</td> <td>64 (50–78)</td> <td>39 (30–49)</td> <td>25</td> </tr> </tbody> </table> <p>Sex and Stage: Localised; regional metastases; distant metastases</p> <table border="1"> <thead> <tr> <th rowspan="2">Stage</th> <th colspan="3">Males</th> <th colspan="3">Females</th> </tr> <tr> <th>45-59 years old</th> <th>≥75 years old</th> <th>Abs. diff.</th> <th>45-59 years old</th> <th>≥75 years old</th> <th>Abs. diff.</th> </tr> </thead> <tbody> <tr> <td></td> <td colspan="6" style="text-align: center;"><b>1-year RS (no 95%CI)</b></td> </tr> <tr> <td>Localised</td> <td>98</td> <td>91</td> <td>7</td> <td>97</td> <td>90</td> <td>7</td> </tr> <tr> <td>Regional</td> <td>90</td> <td>85</td> <td>5</td> <td>85</td> <td>76</td> <td>9</td> </tr> <tr> <td>Distant</td> <td>45</td> <td>26</td> <td>19</td> <td>52</td> <td>28</td> <td>24</td> </tr> <tr> <td></td> <td colspan="6" style="text-align: center;"><b>5-year RS (95%CI)</b></td> </tr> <tr> <td>Localised</td> <td>85 (79–91)</td> <td>79 (69–89)</td> <td>6</td> <td>80 (74–85)</td> <td>82 (76–89)</td> <td>2</td> </tr> <tr> <td>Regional</td> <td>55 (44–66)</td> <td>63 (45–82)</td> <td>-8</td> <td>59 (47–70)</td> <td>49 (39–59)</td> <td>10</td> </tr> <tr> <td>Distant</td> <td>12 (7–16)</td> <td>12 (6–18)</td> <td>0</td> <td>13 (8–19)</td> <td>8 (5–11)</td> <td>5</td> </tr> </tbody> </table>	Subsite	5-year RS (95% CI)		Abs. diff.	45-59 years old	≥75 years old	Caecum & Ascending	53 (48–59)	52 (47–56)	1	Transverse	47 (40–54)	38 (32–45)	9	Descending & Sigmoid	54 (49–59)	48 (43–52)	6	Other	64 (50–78)	39 (30–49)	25	Stage	Males			Females			45-59 years old	≥75 years old	Abs. diff.	45-59 years old	≥75 years old	Abs. diff.		<b>1-year RS (no 95%CI)</b>						Localised	98	91	7	97	90	7	Regional	90	85	5	85	76	9	Distant	45	26	19	52	28	24		<b>5-year RS (95%CI)</b>						Localised	85 (79–91)	79 (69–89)	6	80 (74–85)	82 (76–89)	2	Regional	55 (44–66)	63 (45–82)	-8	59 (47–70)	49 (39–59)	10	Distant	12 (7–16)	12 (6–18)	0	13 (8–19)	8 (5–11)	5
Subsite	5-year RS (95% CI)		Abs. diff.																																																																																																
	45-59 years old	≥75 years old																																																																																																	
Caecum & Ascending	53 (48–59)	52 (47–56)	1																																																																																																
Transverse	47 (40–54)	38 (32–45)	9																																																																																																
Descending & Sigmoid	54 (49–59)	48 (43–52)	6																																																																																																
Other	64 (50–78)	39 (30–49)	25																																																																																																
Stage	Males			Females																																																																																															
	45-59 years old	≥75 years old	Abs. diff.	45-59 years old	≥75 years old	Abs. diff.																																																																																													
	<b>1-year RS (no 95%CI)</b>																																																																																																		
Localised	98	91	7	97	90	7																																																																																													
Regional	90	85	5	85	76	9																																																																																													
Distant	45	26	19	52	28	24																																																																																													
	<b>5-year RS (95%CI)</b>																																																																																																		
Localised	85 (79–91)	79 (69–89)	6	80 (74–85)	82 (76–89)	2																																																																																													
Regional	55 (44–66)	63 (45–82)	-8	59 (47–70)	49 (39–59)	10																																																																																													
Distant	12 (7–16)	12 (6–18)	0	13 (8–19)	8 (5–11)	5																																																																																													

First author, date	Age categories	Sampling	Time zero	End of follow-up	Survival metrics	Method	Sample size	Factors and its definition																											
Van de Schans, et al., 2007 <sup>21</sup>	35-64; ≥65	None	Date of diagnosis	January 1, 2006	OS	Kaplan-Meier	678	<p><u>Chronic obstructive pulmonary disease</u> (COPD - Yes/No – from medical history, use of relevant drugs and diagnostic work-up)</p> <p>No numerical estimates.</p> <p><i>Survival curves presented in Fig.1 (A) of authors' article suggests that age disparities in colon cancer overall survival at 5 years between patients aged 35-64 and those aged 65+ were bigger for patients with COPD than for those free of COPD.</i></p>																											
van Steenbergen et al., 2010 <sup>27</sup>	<65; 65–74; ≥75	None	Cancer diagnosis	January 1, 2008	3,5-year OS	Not mentioned	1,637	<p><u>Treatment: chemotherapy vs. no chemotherapy</u></p> <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th rowspan="2"></th> <th colspan="3">3-year OS</th> </tr> <tr> <th>&lt;65 years old</th> <th>≥75 years old</th> <th>Abs. diff.</th> </tr> </thead> <tbody> <tr> <td>Chemotherapy</td> <td>78</td> <td>63</td> <td>15</td> </tr> <tr> <td>No chemotherapy</td> <td>38</td> <td>45</td> <td>-7</td> </tr> <tr> <th colspan="4">5-year OS</th> </tr> <tr> <td>Chemotherapy</td> <td>66</td> <td>54</td> <td>12</td> </tr> <tr> <td>No chemotherapy</td> <td>27</td> <td>28</td> <td>-1</td> </tr> </tbody> </table>		3-year OS			<65 years old	≥75 years old	Abs. diff.	Chemotherapy	78	63	15	No chemotherapy	38	45	-7	5-year OS				Chemotherapy	66	54	12	No chemotherapy	27	28	-1
	3-year OS																																		
	<65 years old	≥75 years old	Abs. diff.																																
Chemotherapy	78	63	15																																
No chemotherapy	38	45	-7																																
5-year OS																																			
Chemotherapy	66	54	12																																
No chemotherapy	27	28	-1																																
van den Broek et al., 2011 <sup>16</sup>	<65; 65–74; ≥75	None	Not clearly mentioned.	December 31, 2009	5-year RS	Hakulinen	8,926	<p><u>Stage (TNM classification)</u></p> <p>No numerical estimates.</p> <p><i>Fig.2 of authors' article suggests that in 2004, the difference in 5-year RS between patients aged &lt;65 and those aged 75 years or older was similar for stage I and II cancer. The biggest age difference was observed in patients with stage III cancer and the smallest in patients with stage IV cancer.</i></p>																											

First author, date	Age categories	Sampling	Time zero	End of follow-up	Survival metrics	Method	Sample size	Factors and its definition															
Nedrebø et al., 2011 <sup>28</sup>	<75; ≥75	None	Not clearly mentioned.	December 31, 2008	5-year RS	Pohar-Perme	11,437	<p>Presence of lymph node metastases: positive vs. negative</p> <table border="1"> <thead> <tr> <th rowspan="2"></th> <th colspan="3">5-year RS for the period 2001-2003</th> </tr> <tr> <th>≤75 years old</th> <th>&gt;75 years old</th> <th>Abs. diff</th> </tr> </thead> <tbody> <tr> <td>Node positive</td> <td>67.1</td> <td>51.6</td> <td>15.5</td> </tr> <tr> <td>Node negative</td> <td>88.5</td> <td>84.7</td> <td>3.8</td> </tr> </tbody> </table>		5-year RS for the period 2001-2003			≤75 years old	>75 years old	Abs. diff	Node positive	67.1	51.6	15.5	Node negative	88.5	84.7	3.8
	5-year RS for the period 2001-2003																						
	≤75 years old	>75 years old	Abs. diff																				
Node positive	67.1	51.6	15.5																				
Node negative	88.5	84.7	3.8																				
Kolfschoten et al., 2012 <sup>17</sup>	<70; 70–79; ≥80	None	Definitive resection	30-day after the entry in the study	30-day postoperative mortality	None	6,161	<p>Treatment: elective vs. non-elective resection.  Risk factors among male gender, American Society of Anesthesiologists score of III+, Charlson score 2+, metastatic disease or hemicolectomy</p> <p>No numerical estimates.</p> <p><i>In patients who underwent an elective surgery, mortality rates in the absence of risk factors were 0% for patients younger than 80 and around 6% in older patients. When examining individual risk factors, mortality rates were similar in patients aged less than 70 or between 70 and 80; however, rates were much higher in the 80+ age group. Mortality rates increased linearly as age increased in males with no other risk factors. When examining the cumulative effect of risk factors, the difference in mortality rates between patients aged less 70 and those aged 80 + increased as the number of risk factors increased. The biggest age disparities was observed for patients with metastatic cancer; the mortality rates were between 0-3% in patients younger than 80 years old and 10% in older patients.</i></p> <p><i>In patients who underwent a non-elective surgery, age disparities in mortality rates were the lowest in those with no risk factors (around 2% in &lt;70 age group vs. 6-7% in 80+ age group), intermediate in those with a ASA III+ score (around 14% vs. 21%), and the biggest in patients who underwent a hemicolectomy (around 1% in &lt;70 age group vs. 18-19% in 80+ age group). Age disparities increased with the cumulative number of risk factors.</i></p>															

First author, date	Age categories	Sampling	Time zero	End of follow-up	Survival metrics	Method	Sample size	Factors and its definition																																								
Majek et al., 2013 <sup>29</sup>	15–44; 45–54; 55–64; 65–74; ≥75	None	Not clearly mentioned.	Not clearly mentioned	5-year RS	Ederer II; Period analysis	eberl	<p><u>Sex, and subsite (right colon; left colon)</u></p> <table border="1"> <thead> <tr> <th rowspan="3"></th> <th colspan="6">5-year RS</th> </tr> <tr> <th colspan="3">Males</th> <th colspan="3">Females</th> </tr> <tr> <th>45-54 year old</th> <th>≥75 year old</th> <th>Abs. diff</th> <th>45-54 year old</th> <th>≥75 year old</th> <th>Abs. diff</th> </tr> </thead> <tbody> <tr> <td>Subsite</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Right colon</td> <td>61.7</td> <td>61.5</td> <td>0.2</td> <td>64.1</td> <td>64.3</td> <td>-0.2</td> </tr> <tr> <td>Left colon</td> <td>65.4</td> <td>58.9</td> <td>6.5</td> <td>67.9</td> <td>58.6</td> <td>9.3</td> </tr> </tbody> </table>		5-year RS						Males			Females			45-54 year old	≥75 year old	Abs. diff	45-54 year old	≥75 year old	Abs. diff	Subsite							Right colon	61.7	61.5	0.2	64.1	64.3	-0.2	Left colon	65.4	58.9	6.5	67.9	58.6	9.3
	5-year RS																																															
	Males			Females																																												
	45-54 year old	≥75 year old	Abs. diff	45-54 year old	≥75 year old	Abs. diff																																										
Subsite																																																
Right colon	61.7	61.5	0.2	64.1	64.3	-0.2																																										
Left colon	65.4	58.9	6.5	67.9	58.6	9.3																																										
Park et al., 2013 <sup>36</sup>	<70; ≥70	None	Not clearly mentioned.	Not mentioned	5-year RS	Ederer II	226,352	<p><u>Subsite: proximal colon (C18.0–C18.5); distal colon (C18.6–C18.7)</u></p> <table border="1"> <thead> <tr> <th rowspan="2"></th> <th colspan="3">5-year RS (95% CI)</th> </tr> <tr> <th>&lt;70 years old</th> <th>≥70 years old</th> <th>Abs. diff</th> </tr> </thead> <tbody> <tr> <td>Subsites</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Proximal colon</td> <td>71.1 (70.5–71.7)</td> <td>57.8 (56.6–58.9)</td> <td>13.3</td> </tr> <tr> <td>Distal colon</td> <td>74.2 (73.6–74.7)</td> <td>61.8 (60.7–63.0)</td> <td>12.4</td> </tr> <tr> <td colspan="4"><b>Among stage IV</b></td> </tr> <tr> <td>Proximal colon</td> <td>21.3 (19.4–23.3)</td> <td>9.3 (7.3–11.6)</td> <td>12.0</td> </tr> <tr> <td>Distal colon</td> <td>23.8 (22.0–25.6)</td> <td>15.0 (12.6–17.6)</td> <td>8.8</td> </tr> </tbody> </table>		5-year RS (95% CI)			<70 years old	≥70 years old	Abs. diff	Subsites				Proximal colon	71.1 (70.5–71.7)	57.8 (56.6–58.9)	13.3	Distal colon	74.2 (73.6–74.7)	61.8 (60.7–63.0)	12.4	<b>Among stage IV</b>				Proximal colon	21.3 (19.4–23.3)	9.3 (7.3–11.6)	12.0	Distal colon	23.8 (22.0–25.6)	15.0 (12.6–17.6)	8.8									
	5-year RS (95% CI)																																															
	<70 years old	≥70 years old	Abs. diff																																													
Subsites																																																
Proximal colon	71.1 (70.5–71.7)	57.8 (56.6–58.9)	13.3																																													
Distal colon	74.2 (73.6–74.7)	61.8 (60.7–63.0)	12.4																																													
<b>Among stage IV</b>																																																
Proximal colon	21.3 (19.4–23.3)	9.3 (7.3–11.6)	12.0																																													
Distal colon	23.8 (22.0–25.6)	15.0 (12.6–17.6)	8.8																																													

First author, date	Age categories	Sampling	Time zero	End of follow-up	Survival metrics	Method	Sample size	Factors and its definition																																																												
Van Steenberg et al., 2013 <sup>30</sup>	15-44; 45-59; 60-74; 75-89	None	Not clearly mentioned.	January, 2010	5-year RS conditioning on surviving 0,3,5,10 years	Ederer II; Period analysis	89,451	<u>Stage (TNM classification)</u> <table border="1" style="margin-left: 20px;"> <thead> <tr> <th colspan="4">5-year RS (95% CI) conditioning on surviving 0,3,5 years after cancer diagnosis</th> </tr> <tr> <th></th> <th>45-59 years old</th> <th>75-89 years old</th> <th>Abs. diff.</th> </tr> </thead> <tbody> <tr> <td colspan="4" style="text-align: center;">0 years</td> </tr> <tr> <td>Stage</td> <td colspan="3"></td> </tr> <tr> <td>I</td> <td>94 (93-96)</td> <td>92 (90-94)</td> <td>2</td> </tr> <tr> <td>II</td> <td>81 (80-83)</td> <td>76 (75-77)</td> <td>5</td> </tr> <tr> <td>III</td> <td>63 (62-65)</td> <td>49 (47-51)</td> <td>14</td> </tr> <tr> <td colspan="4" style="text-align: center;">3 years</td> </tr> <tr> <td>I</td> <td>95 (94-97)</td> <td>100 (96-103)</td> <td>-5</td> </tr> <tr> <td>II</td> <td>88 (87-90)</td> <td>95 (93-97)</td> <td>-7</td> </tr> <tr> <td>III</td> <td>77 (75-79)</td> <td>84 (80-87)</td> <td>-7</td> </tr> <tr> <td colspan="4" style="text-align: center;">5 years</td> </tr> <tr> <td>I</td> <td>96 (94-97)</td> <td>103 (98-107)</td> <td>-7</td> </tr> <tr> <td>II</td> <td>92 (91-94)</td> <td>99 (96-102)</td> <td>-7</td> </tr> <tr> <td>III</td> <td>88 (86-90)</td> <td>97 (92-102)</td> <td>-9</td> </tr> </tbody> </table>	5-year RS (95% CI) conditioning on surviving 0,3,5 years after cancer diagnosis					45-59 years old	75-89 years old	Abs. diff.	0 years				Stage				I	94 (93-96)	92 (90-94)	2	II	81 (80-83)	76 (75-77)	5	III	63 (62-65)	49 (47-51)	14	3 years				I	95 (94-97)	100 (96-103)	-5	II	88 (87-90)	95 (93-97)	-7	III	77 (75-79)	84 (80-87)	-7	5 years				I	96 (94-97)	103 (98-107)	-7	II	92 (91-94)	99 (96-102)	-7	III	88 (86-90)	97 (92-102)	-9
5-year RS (95% CI) conditioning on surviving 0,3,5 years after cancer diagnosis																																																																				
	45-59 years old	75-89 years old	Abs. diff.																																																																	
0 years																																																																				
Stage																																																																				
I	94 (93-96)	92 (90-94)	2																																																																	
II	81 (80-83)	76 (75-77)	5																																																																	
III	63 (62-65)	49 (47-51)	14																																																																	
3 years																																																																				
I	95 (94-97)	100 (96-103)	-5																																																																	
II	88 (87-90)	95 (93-97)	-7																																																																	
III	77 (75-79)	84 (80-87)	-7																																																																	
5 years																																																																				
I	96 (94-97)	103 (98-107)	-7																																																																	
II	92 (91-94)	99 (96-102)	-7																																																																	
III	88 (86-90)	97 (92-102)	-9																																																																	
Khan et al., 2014 <sup>31</sup>	20-49; 50-64; 65-74; 75-84; ≥ 85	None	Not clearly mentioned.	December 31, 2010	Cumulative Incidence of death at 5 years	Cronin and Feuer's	191,967	<u>Number of lymph nodes examined</u> <table border="1" style="margin-left: 20px;"> <thead> <tr> <th colspan="4">Cumulative incidence of death at 5 years (%)</th> </tr> <tr> <th></th> <th>50-64 years old</th> <th>≥ 85 years old</th> <th>Abs. Diff</th> </tr> </thead> <tbody> <tr> <td>0-11 Lymph nodes</td> <td>18.4</td> <td>27.5</td> <td>-9.1</td> </tr> <tr> <td>≥12 lymph nodes</td> <td>16.7</td> <td>17.8</td> <td>-1.1</td> </tr> </tbody> </table>	Cumulative incidence of death at 5 years (%)					50-64 years old	≥ 85 years old	Abs. Diff	0-11 Lymph nodes	18.4	27.5	-9.1	≥12 lymph nodes	16.7	17.8	-1.1																																												
Cumulative incidence of death at 5 years (%)																																																																				
	50-64 years old	≥ 85 years old	Abs. Diff																																																																	
0-11 Lymph nodes	18.4	27.5	-9.1																																																																	
≥12 lymph nodes	16.7	17.8	-1.1																																																																	



First author, date	Age categories	Sampling	Time zero	End of follow-up	Survival metrics	Method	Sample size	Factors and its definition																
Mariotto et al., 2014 <sup>54</sup>	20-44; 45-54; 55-64; 65-74; ≥75	None	Date of diagnosis	December 31, 2010	5-year RS	Ederer II	126,715	<u>Sex</u> <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th colspan="4">5-year RS (95% CI)</th> </tr> <tr> <th></th> <th>45-54 years old</th> <th>≥75 years old</th> <th>Abs. diff</th> </tr> </thead> <tbody> <tr> <td>Males</td> <td>68 (66-69)</td> <td>60 (58-61)</td> <td>8</td> </tr> <tr> <td>Females</td> <td>68 (67-70)</td> <td>59 (58-60)</td> <td>9</td> </tr> </tbody> </table>	5-year RS (95% CI)					45-54 years old	≥75 years old	Abs. diff	Males	68 (66-69)	60 (58-61)	8	Females	68 (67-70)	59 (58-60)	9
5-year RS (95% CI)																								
	45-54 years old	≥75 years old	Abs. diff																					
Males	68 (66-69)	60 (58-61)	8																					
Females	68 (67-70)	59 (58-60)	9																					
Aan De Stegge et al., 2016 <sup>32</sup>	< 66; 66–75; >75	None	Not mentioned.	December, 2010	5-year OS	Kaplan-Meier	41,074	<u>Number of lymph nodes examined</u> <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th colspan="4">5-year OS</th> </tr> <tr> <th></th> <th>&lt;66 years old</th> <th>&gt;75 years old</th> <th>Abs. Diff</th> </tr> </thead> <tbody> <tr> <td>0-11 lymph nodes</td> <td>79</td> <td>45</td> <td>34</td> </tr> <tr> <td>≥12 lymph nodes</td> <td>81</td> <td>53</td> <td>28</td> </tr> </tbody> </table>	5-year OS					<66 years old	>75 years old	Abs. Diff	0-11 lymph nodes	79	45	34	≥12 lymph nodes	81	53	28
5-year OS																								
	<66 years old	>75 years old	Abs. Diff																					
0-11 lymph nodes	79	45	34																					
≥12 lymph nodes	81	53	28																					
Hines et al., 2016 <sup>33</sup>	40-64; 65-74; 75-84	None	Cancer diagnosis	January 1, 2012	Adjusted mortality rates	Poisson regression model	3,057	<u>Treatment: Chemotherapy</u> : receipt of ACT had to occur within 120 days of surgery <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th colspan="4">5-year mortality rate per 1,000 person.year (95%CI)</th> </tr> <tr> <th></th> <th>60-64 years old</th> <th>75-84 years old</th> <th>Abs. Diff</th> </tr> </thead> <tbody> <tr> <td>Chemotherapy</td> <td>49.7 (33.9–73.1)</td> <td>138.7 (85.2–225.9)</td> <td>89.0</td> </tr> <tr> <td>No chemotherapy</td> <td>68.8 (45.7–103.6)</td> <td>193.1 (120.0–310.5)</td> <td>124.3</td> </tr> </tbody> </table>	5-year mortality rate per 1,000 person.year (95%CI)					60-64 years old	75-84 years old	Abs. Diff	Chemotherapy	49.7 (33.9–73.1)	138.7 (85.2–225.9)	89.0	No chemotherapy	68.8 (45.7–103.6)	193.1 (120.0–310.5)	124.3
5-year mortality rate per 1,000 person.year (95%CI)																								
	60-64 years old	75-84 years old	Abs. Diff																					
Chemotherapy	49.7 (33.9–73.1)	138.7 (85.2–225.9)	89.0																					
No chemotherapy	68.8 (45.7–103.6)	193.1 (120.0–310.5)	124.3																					

First author, date	Age categories	Sampling	Time zero	End of follow-up	Survival metrics	Method	Sample size	Factors and its definition																																																																	
Aquina et al., 2017 <sup>34</sup>	<65; 65-74; ≥75	None	Date of surgery	December 31, 2012	1-year overall mortality rate	-	24,426	<p><u>Complications and sepsis</u></p> <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th colspan="5">1-year mortality rate (%)</th> </tr> <tr> <th></th> <th>&lt;65</th> <th>≥ 75</th> <th>p</th> <th>Abs. Diff</th> </tr> </thead> <tbody> <tr> <td>No complications</td> <td>1.9</td> <td>9.2</td> <td rowspan="2">&lt;0.0001</td> <td>7.3</td> </tr> <tr> <td>Complications</td> <td>6.4</td> <td>22.4</td> <td>16.0</td> </tr> <tr> <td>No sepsis</td> <td>2.4</td> <td>12.1</td> <td rowspan="2">&lt;0.0001</td> <td>9.7</td> </tr> <tr> <td>Sepsis</td> <td>16</td> <td>43.3</td> <td>27.3</td> </tr> </tbody> </table>	1-year mortality rate (%)						<65	≥ 75	p	Abs. Diff	No complications	1.9	9.2	<0.0001	7.3	Complications	6.4	22.4	16.0	No sepsis	2.4	12.1	<0.0001	9.7	Sepsis	16	43.3	27.3																																					
1-year mortality rate (%)																																																																									
	<65	≥ 75	p	Abs. Diff																																																																					
No complications	1.9	9.2	<0.0001	7.3																																																																					
Complications	6.4	22.4		16.0																																																																					
No sepsis	2.4	12.1	<0.0001	9.7																																																																					
Sepsis	16	43.3		27.3																																																																					
Brungs et al., 2018 <sup>20</sup>	<70; ≥70	None	Not mentioned	December 1, 2014	12-month landmark overall mortality  1,3,5-year OS  Among those who survive 30 days	Mortality rate Kaplan-Meier	2,164	<p><u>Treatment: adjuvant oxaliplatin doublet chemotherapy vs. fluoropyrimidine monotherapy</u></p> <p>OS estimates provided by the first author.</p> <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th></th> <th>&lt;70 year old</th> <th>≥70 years old</th> <th>p</th> <th>Abs. Diff</th> </tr> </thead> <tbody> <tr> <td colspan="5" style="text-align: center;">12-month mortality rate</td> </tr> <tr> <td>Oxaliplatin</td> <td>1.7</td> <td>5.9</td> <td>0.006</td> <td>4.2</td> </tr> <tr> <td>Fluoropyrimidine</td> <td>4.5</td> <td>8.6</td> <td>0.06</td> <td>4.1</td> </tr> <tr> <td colspan="5" style="text-align: center;">1-year OS</td> </tr> <tr> <td>Oxaliplatin</td> <td>98.2</td> <td>94.2</td> <td></td> <td>4.0</td> </tr> <tr> <td>Fluoropyrimidine</td> <td>94.3</td> <td>91.1</td> <td></td> <td>3.2</td> </tr> <tr> <td colspan="5" style="text-align: center;">3-year OS</td> </tr> <tr> <td>Oxaliplatin</td> <td>87.7</td> <td>77.9</td> <td></td> <td>9.8</td> </tr> <tr> <td>Fluoropyrimidine</td> <td>83.8</td> <td>70.9</td> <td></td> <td>12.9</td> </tr> <tr> <td colspan="5" style="text-align: center;">5-year OS</td> </tr> <tr> <td>Oxaliplatin</td> <td>80.8</td> <td>77.9</td> <td></td> <td>2.9</td> </tr> <tr> <td>Fluoropyrimidine</td> <td>68.2</td> <td>60.9</td> <td></td> <td>7.3</td> </tr> </tbody> </table>		<70 year old	≥70 years old	p	Abs. Diff	12-month mortality rate					Oxaliplatin	1.7	5.9	0.006	4.2	Fluoropyrimidine	4.5	8.6	0.06	4.1	1-year OS					Oxaliplatin	98.2	94.2		4.0	Fluoropyrimidine	94.3	91.1		3.2	3-year OS					Oxaliplatin	87.7	77.9		9.8	Fluoropyrimidine	83.8	70.9		12.9	5-year OS					Oxaliplatin	80.8	77.9		2.9	Fluoropyrimidine	68.2	60.9		7.3
	<70 year old	≥70 years old	p	Abs. Diff																																																																					
12-month mortality rate																																																																									
Oxaliplatin	1.7	5.9	0.006	4.2																																																																					
Fluoropyrimidine	4.5	8.6	0.06	4.1																																																																					
1-year OS																																																																									
Oxaliplatin	98.2	94.2		4.0																																																																					
Fluoropyrimidine	94.3	91.1		3.2																																																																					
3-year OS																																																																									
Oxaliplatin	87.7	77.9		9.8																																																																					
Fluoropyrimidine	83.8	70.9		12.9																																																																					
5-year OS																																																																									
Oxaliplatin	80.8	77.9		2.9																																																																					
Fluoropyrimidine	68.2	60.9		7.3																																																																					

First author, date	Age categories	Sampling	Time zero	End of follow-up	Survival metrics	Method	Sample size	Factors and its definition																								
Hur et al., 2018 <sup>35</sup>	<39; 40–49; 50–59; 60–69; ≥70	None	Not mentioned.	Not mentioned	5-year RS	Ederer II	326,712	Subsites (right side, transverse, left side) <table border="1" style="margin-left: 20px;"> <thead> <tr> <th></th> <th colspan="3">5-year RS (95% CI)</th> </tr> <tr> <th></th> <th>50-59 years old</th> <th>≥70 years old</th> <th>Abs. diff</th> </tr> </thead> <tbody> <tr> <td>Subsites</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Right side</td> <td>80.5 (79.0–82.0)</td> <td>64.9 (63.4–66.4)</td> <td>15.6</td> </tr> <tr> <td>Transverse</td> <td>83.3 (80.2–86.1)</td> <td>66.1 (62.9–69.2)</td> <td>17.2</td> </tr> <tr> <td>Left side</td> <td>83.8 (82.8–84.8)</td> <td>69.1 (67.7–70.5)</td> <td>14.7</td> </tr> </tbody> </table>		5-year RS (95% CI)				50-59 years old	≥70 years old	Abs. diff	Subsites				Right side	80.5 (79.0–82.0)	64.9 (63.4–66.4)	15.6	Transverse	83.3 (80.2–86.1)	66.1 (62.9–69.2)	17.2	Left side	83.8 (82.8–84.8)	69.1 (67.7–70.5)	14.7
	5-year RS (95% CI)																															
	50-59 years old	≥70 years old	Abs. diff																													
Subsites																																
Right side	80.5 (79.0–82.0)	64.9 (63.4–66.4)	15.6																													
Transverse	83.3 (80.2–86.1)	66.1 (62.9–69.2)	17.2																													
Left side	83.8 (82.8–84.8)	69.1 (67.7–70.5)	14.7																													

**Table 5 Data extraction of included studies about age disparities in lung cancer survival**

First author, date	Age categories	Time zero	End of follow-up	Survival metrics	Method	Sample size	Factors studied and results																																																																													
<b>Lung cancer</b>																																																																																				
Wingo et al., 1998 <sup>37</sup>	<45;45-54;55-64;65-74;≥75	Not mentioned.	1992	5-year RS	Ederer I	161,812 white men and women + 19,242 black men and women	Sex, Race and Stage (SEER staging) <table border="1" style="margin-left: 20px;"> <thead> <tr> <th colspan="7">5-year RS</th> </tr> <tr> <th colspan="3">Males</th> <th colspan="4">Females</th> </tr> <tr> <th></th> <th>45-54 years old</th> <th>≥ 75 years old</th> <th>Abs. Diff</th> <th>45-54 years old</th> <th>≥ 75 years old</th> <th>Abs. Diff</th> </tr> </thead> <tbody> <tr> <td colspan="7" style="text-align: center;">White</td> </tr> <tr> <td>Local</td> <td>49</td> <td>20</td> <td>29</td> <td>61</td> <td>30</td> <td>31</td> </tr> <tr> <td>Regional</td> <td>17</td> <td>7</td> <td>10</td> <td>22</td> <td>12</td> <td>10</td> </tr> <tr> <td>Distant</td> <td>2</td> <td>1</td> <td>1</td> <td>3</td> <td>1</td> <td>2</td> </tr> <tr> <td colspan="7" style="text-align: center;">Black</td> </tr> <tr> <td>Local</td> <td>36</td> <td>16</td> <td>20</td> <td>47</td> <td>24</td> <td>23</td> </tr> <tr> <td>Regional</td> <td>13</td> <td>4</td> <td>9</td> <td>16</td> <td>8</td> <td>8</td> </tr> <tr> <td>Distant</td> <td>2</td> <td>1</td> <td>1</td> <td>2</td> <td>1</td> <td>1</td> </tr> </tbody> </table>	5-year RS							Males			Females					45-54 years old	≥ 75 years old	Abs. Diff	45-54 years old	≥ 75 years old	Abs. Diff	White							Local	49	20	29	61	30	31	Regional	17	7	10	22	12	10	Distant	2	1	1	3	1	2	Black							Local	36	16	20	47	24	23	Regional	13	4	9	16	8	8	Distant	2	1	1	2	1	1
5-year RS																																																																																				
Males			Females																																																																																	
	45-54 years old	≥ 75 years old	Abs. Diff	45-54 years old	≥ 75 years old	Abs. Diff																																																																														
White																																																																																				
Local	49	20	29	61	30	31																																																																														
Regional	17	7	10	22	12	10																																																																														
Distant	2	1	1	3	1	2																																																																														
Black																																																																																				
Local	36	16	20	47	24	23																																																																														
Regional	13	4	9	16	8	8																																																																														
Distant	2	1	1	2	1	1																																																																														

First author, date	Age categories	Time zero	End of follow-up	Survival metrics	Method	Sample size	Factors studied and results																																																																																																	
Dickman et al., 1999 <sup>53</sup>	30-44; 45-59; 60-74; ≥75	Cancer diagnosis	December 31, 1995	1, 5-year RS	Hakulin en	Not mentioned	<p>Sex, stage (SEER staging), and histology</p> <table border="1"> <thead> <tr> <th rowspan="2"></th> <th colspan="3">Male</th> <th colspan="3">female</th> </tr> <tr> <th>45-59 years old</th> <th>≥75 years old</th> <th>Abs. diff</th> <th>45-59 years old</th> <th>≥75 years old</th> <th>Abs. diff</th> </tr> </thead> <tbody> <tr> <td>Stage</td> <td colspan="6">1-year RS</td> </tr> <tr> <td>Localised</td> <td>80</td> <td>56</td> <td>24</td> <td>91</td> <td>48</td> <td>43</td> </tr> <tr> <td>Regional</td> <td>62</td> <td>41</td> <td>21</td> <td>64</td> <td>30</td> <td>34</td> </tr> <tr> <td>Distant</td> <td>22</td> <td>15</td> <td>7</td> <td>27</td> <td>13</td> <td>14</td> </tr> <tr> <td></td> <td colspan="6">5-year RS (95% CI)</td> </tr> <tr> <td>Localised</td> <td>41 (36-45)</td> <td>10 (7-13)</td> <td>31</td> <td>56 (46-66)</td> <td>8 (2-15)</td> <td>48</td> </tr> <tr> <td>Regional</td> <td>15 (11-20)</td> <td>4 (0-9)</td> <td>11</td> <td>15 (7-24)</td> <td>10 (0-21)</td> <td>5</td> </tr> <tr> <td>Distant</td> <td>2 (1-2)</td> <td>1 (0-1)</td> <td>1</td> <td>3 (1-5)</td> <td>1 (0-2)</td> <td>2</td> </tr> <tr> <td>Histology</td> <td colspan="6"></td> </tr> <tr> <td>Squamous cell carcinoma</td> <td>20 (17-23)</td> <td>6 (4-8)</td> <td>14</td> <td>19 (11-27)</td> <td>5 (0-9)</td> <td>14</td> </tr> <tr> <td>Small cell carcinoma</td> <td>4 (2-6)</td> <td>3 (1-5)</td> <td>1</td> <td>9 (4-15)</td> <td>..</td> <td>-</td> </tr> <tr> <td>Adenocarcinoma</td> <td>19 (15-23)</td> <td>6 (2-10)</td> <td>13</td> <td>26 (19-32)</td> <td>7 (2-12)</td> <td>19</td> </tr> </tbody> </table>		Male			female			45-59 years old	≥75 years old	Abs. diff	45-59 years old	≥75 years old	Abs. diff	Stage	1-year RS						Localised	80	56	24	91	48	43	Regional	62	41	21	64	30	34	Distant	22	15	7	27	13	14		5-year RS (95% CI)						Localised	41 (36-45)	10 (7-13)	31	56 (46-66)	8 (2-15)	48	Regional	15 (11-20)	4 (0-9)	11	15 (7-24)	10 (0-21)	5	Distant	2 (1-2)	1 (0-1)	1	3 (1-5)	1 (0-2)	2	Histology							Squamous cell carcinoma	20 (17-23)	6 (4-8)	14	19 (11-27)	5 (0-9)	14	Small cell carcinoma	4 (2-6)	3 (1-5)	1	9 (4-15)	..	-	Adenocarcinoma	19 (15-23)	6 (2-10)	13	26 (19-32)	7 (2-12)	19
	Male			female																																																																																																				
	45-59 years old	≥75 years old	Abs. diff	45-59 years old	≥75 years old	Abs. diff																																																																																																		
Stage	1-year RS																																																																																																							
Localised	80	56	24	91	48	43																																																																																																		
Regional	62	41	21	64	30	34																																																																																																		
Distant	22	15	7	27	13	14																																																																																																		
	5-year RS (95% CI)																																																																																																							
Localised	41 (36-45)	10 (7-13)	31	56 (46-66)	8 (2-15)	48																																																																																																		
Regional	15 (11-20)	4 (0-9)	11	15 (7-24)	10 (0-21)	5																																																																																																		
Distant	2 (1-2)	1 (0-1)	1	3 (1-5)	1 (0-2)	2																																																																																																		
Histology																																																																																																								
Squamous cell carcinoma	20 (17-23)	6 (4-8)	14	19 (11-27)	5 (0-9)	14																																																																																																		
Small cell carcinoma	4 (2-6)	3 (1-5)	1	9 (4-15)	..	-																																																																																																		
Adenocarcinoma	19 (15-23)	6 (2-10)	13	26 (19-32)	7 (2-12)	19																																																																																																		

First author, date	Age categories	Time zero	End of follow-up	Survival metrics	Method	Sample size	Factors studied and results																																								
Chang et al., 2012 <sup>38</sup>	<65; ≥65	Cancer diagnosis	2007	5-year OS	Survival curves	4,698	<p>Socio-economic status (SES)</p> <ul style="list-style-type: none"> <li>- <u>individual level</u>: income-related insurance payment amount at the time of diagnosis</li> <li>- <u>neighbourhood level</u>: per capita personal income by township acquired from the 2001 income tax statistics released Taiwan's Ministry of Finance.</li> </ul> <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th colspan="4">5-year OS</th> </tr> <tr> <th></th> <th>&lt; 65 years old</th> <th>≥65 years old</th> <th>Abs. Diff</th> </tr> </thead> <tbody> <tr> <td colspan="4" style="text-align: center;">Advantaged neighborhood</td> </tr> <tr> <td>High SES</td> <td>29.4</td> <td>23.6</td> <td>5.8</td> </tr> <tr> <td>Moderate SES</td> <td>25.4</td> <td>18.1</td> <td>7.3</td> </tr> <tr> <td>Low SES</td> <td>20.9</td> <td>20.2</td> <td>0.7</td> </tr> <tr> <td colspan="4" style="text-align: center;">Disadvantaged neighborhood</td> </tr> <tr> <td>High SES</td> <td>35.3</td> <td>21.9</td> <td>13.4</td> </tr> <tr> <td>Moderate SES</td> <td>25.8</td> <td>28.3</td> <td>-2.5</td> </tr> <tr> <td>Low SES</td> <td>22.5</td> <td>17.0</td> <td>5.5</td> </tr> </tbody> </table>	5-year OS					< 65 years old	≥65 years old	Abs. Diff	Advantaged neighborhood				High SES	29.4	23.6	5.8	Moderate SES	25.4	18.1	7.3	Low SES	20.9	20.2	0.7	Disadvantaged neighborhood				High SES	35.3	21.9	13.4	Moderate SES	25.8	28.3	-2.5	Low SES	22.5	17.0	5.5
5-year OS																																															
	< 65 years old	≥65 years old	Abs. Diff																																												
Advantaged neighborhood																																															
High SES	29.4	23.6	5.8																																												
Moderate SES	25.4	18.1	7.3																																												
Low SES	20.9	20.2	0.7																																												
Disadvantaged neighborhood																																															
High SES	35.3	21.9	13.4																																												
Moderate SES	25.8	28.3	-2.5																																												
Low SES	22.5	17.0	5.5																																												
Jung et al., 2013 <sup>39</sup>	20-49; 50-64; 65-74; ≥75	Cancer diagnosis	December 31,2011	5-year RS	Ederer II	81,942	<p>Stage (SEER staging).</p> <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th colspan="4">5-year RS (sd)</th> </tr> <tr> <th></th> <th>50-64 years old</th> <th>≥75 years old</th> <th>Abs. Diff</th> </tr> </thead> <tbody> <tr> <td>Localised</td> <td>64.4 (0.9)</td> <td>20.5 (1.2)</td> <td>43.9</td> </tr> <tr> <td>Regional</td> <td>37.3 (0.8)</td> <td>12.4 (0.8)</td> <td>24.9</td> </tr> <tr> <td>Distant</td> <td>6.8 (0.4)</td> <td>2.6 (0.3)</td> <td>4.2</td> </tr> <tr> <td>Unknown</td> <td>25.6 (1.0)</td> <td>8.8 (0.6)</td> <td>16.8</td> </tr> </tbody> </table>	5-year RS (sd)					50-64 years old	≥75 years old	Abs. Diff	Localised	64.4 (0.9)	20.5 (1.2)	43.9	Regional	37.3 (0.8)	12.4 (0.8)	24.9	Distant	6.8 (0.4)	2.6 (0.3)	4.2	Unknown	25.6 (1.0)	8.8 (0.6)	16.8																
5-year RS (sd)																																															
	50-64 years old	≥75 years old	Abs. Diff																																												
Localised	64.4 (0.9)	20.5 (1.2)	43.9																																												
Regional	37.3 (0.8)	12.4 (0.8)	24.9																																												
Distant	6.8 (0.4)	2.6 (0.3)	4.2																																												
Unknown	25.6 (1.0)	8.8 (0.6)	16.8																																												

Mariotto et al., 2014 <sup>54</sup>	20-44; 45-54; 55-64; 65-74; ≥75	Date of diagnosis	December 31, 2010	5-year RS 5-year OS	Ederer II	227,424	Stage (TNM classification), morphology, and sex						
							5-year RS						
							Males			Females			
							45-54 years old	≥75 years old	Abs. diff	45-54 years old	≥75 years old	Abs. diff	
							<i>All Stages</i>	15 (14-16)	11 (10-11)	4	22 (21-23)	13 (13-14)	9
							Small cell	7 (6-9)	3 (2-4)	4	11 (9-13)	4 (3-5)	7
							Non-Small cell	16 (15-17)	11 (11-12)	5	24 (23-25)	14 (14-15)	10
							<i>Stage I</i>	61 (57-64)	42 (39-44)	19	72 (69-75)	50 (48-52)	22
							Small cell	25 (10-43)	13 (6-21)	12	36 (22-49)	18 (11-27)	18
							Non-Small cell	62 (59-66)	43 (40-45)	19	74 (71-77)	51 (49-53)	23
							<i>Stage II</i>	41 (36-47)	22 (18-25)	19	48 (42-54)	22 (19-26)	26
							Small cell	23 (9-41)	-	-	28 (11-47)	10 (4-20)	18
							Non-Small cell	43 (37-48)	22 (19-26)	21	50 (44-56)	23 (20-27)	27
							<i>Stage III</i>	17 (15-18)	7 (7-8)	10	24 (22-26)	9 (8-10)	15
							Small cell	15 (11-19)	4 (3-6)	11	19 (15-24)	6 (4-9)	13
							Non-Small cell	17 (15-19)	8 (7-9)	9	25 (23-28)	9 (8-10)	16
							<i>Stage IV</i>	4 (3-4)	2 (1-2)	2	5 (5-6)	3 (2-3)	2
Small cell	3 (2-4)	1 (0-1)	2	3 (2-5)	1 (1-2)	2							
Non-Small cell	4 (3-4)	2 (2-2)	2	6 (5-7)	3 (2-3)	3							

							<u>Stage (SEER Staging), comorbidities, and sex</u> <table border="1"> <thead> <tr> <th rowspan="3"></th> <th colspan="6">5-year OS</th> </tr> <tr> <th colspan="3">Males</th> <th colspan="3">Females</th> </tr> <tr> <th>66-74 years old</th> <th>≥85 years old</th> <th>Abs. diff</th> <th>66-74 years old</th> <th>≥85 years old</th> <th>Abs. diff</th> </tr> </thead> <tbody> <tr> <td><i>Localised stage</i></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>No comorbidities</td> <td>49</td> <td>16</td> <td>33</td> <td>63</td> <td>18</td> <td>45</td> </tr> <tr> <td>Severe comorbidities</td> <td>29</td> <td>10</td> <td>19</td> <td>38</td> <td>11</td> <td>27</td> </tr> <tr> <td><i>Regional Stage</i></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>No comorbidities</td> <td>21</td> <td>4</td> <td>17</td> <td>30</td> <td>9</td> <td>21</td> </tr> <tr> <td>Severe comorbidities</td> <td>14</td> <td>3</td> <td>11</td> <td>18</td> <td>5</td> <td>13</td> </tr> <tr> <td><i>Distant Stage</i></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>No comorbidities</td> <td>3</td> <td>1</td> <td>2</td> <td>4</td> <td>2</td> <td>2</td> </tr> <tr> <td>Severe comorbidities</td> <td>2</td> <td>1</td> <td>1</td> <td>2</td> <td>0</td> <td>2</td> </tr> </tbody> </table>		5-year OS						Males			Females			66-74 years old	≥85 years old	Abs. diff	66-74 years old	≥85 years old	Abs. diff	<i>Localised stage</i>							No comorbidities	49	16	33	63	18	45	Severe comorbidities	29	10	19	38	11	27	<i>Regional Stage</i>							No comorbidities	21	4	17	30	9	21	Severe comorbidities	14	3	11	18	5	13	<i>Distant Stage</i>							No comorbidities	3	1	2	4	2	2	Severe comorbidities	2	1	1	2	0	2
	5-year OS																																																																																								
	Males			Females																																																																																					
	66-74 years old	≥85 years old	Abs. diff	66-74 years old	≥85 years old	Abs. diff																																																																																			
<i>Localised stage</i>																																																																																									
No comorbidities	49	16	33	63	18	45																																																																																			
Severe comorbidities	29	10	19	38	11	27																																																																																			
<i>Regional Stage</i>																																																																																									
No comorbidities	21	4	17	30	9	21																																																																																			
Severe comorbidities	14	3	11	18	5	13																																																																																			
<i>Distant Stage</i>																																																																																									
No comorbidities	3	1	2	4	2	2																																																																																			
Severe comorbidities	2	1	1	2	0	2																																																																																			
Maringe et al., 2015 <sup>40</sup>	15-44;45-54;55-64;65-69	Cancer diagnosis	December 31, 2007	Net survival	Pohar-Perme	156,094 non-South Asians +1,536 South-Asians	<u>Ethnicity (only in Males)</u> <table border="1"> <thead> <tr> <th rowspan="2"></th> <th>45-54 years old</th> <th>65-69 years old</th> <th>Abs. diff</th> </tr> </thead> <tbody> <tr> <td colspan="4" style="text-align: center;">1-year NS</td> </tr> <tr> <td>South Asians</td> <td>39.5 (30.3-48.7)</td> <td>28.9 (23.7-34.0)</td> <td>10.6</td> </tr> <tr> <td>non-South Asians</td> <td>31.1 (30.1-32.0)</td> <td>26.1 (25.5-26.6)</td> <td>4.9</td> </tr> <tr> <td colspan="4" style="text-align: center;">5-year NS</td> </tr> <tr> <td>South Asians</td> <td>18.9 (11.4-26.4)</td> <td>10.6 (6.9-14.4)</td> <td>8.3</td> </tr> <tr> <td>non-South Asians</td> <td>8.9 (8.3-9.5)</td> <td>7.2 (6.8-7.5)</td> <td>1.7</td> </tr> </tbody> </table>		45-54 years old	65-69 years old	Abs. diff	1-year NS				South Asians	39.5 (30.3-48.7)	28.9 (23.7-34.0)	10.6	non-South Asians	31.1 (30.1-32.0)	26.1 (25.5-26.6)	4.9	5-year NS				South Asians	18.9 (11.4-26.4)	10.6 (6.9-14.4)	8.3	non-South Asians	8.9 (8.3-9.5)	7.2 (6.8-7.5)	1.7																																																						
	45-54 years old	65-69 years old	Abs. diff																																																																																						
	1-year NS																																																																																								
South Asians	39.5 (30.3-48.7)	28.9 (23.7-34.0)	10.6																																																																																						
non-South Asians	31.1 (30.1-32.0)	26.1 (25.5-26.6)	4.9																																																																																						
5-year NS																																																																																									
South Asians	18.9 (11.4-26.4)	10.6 (6.9-14.4)	8.3																																																																																						
non-South Asians	8.9 (8.3-9.5)	7.2 (6.8-7.5)	1.7																																																																																						
Petera et al., 2015 <sup>41</sup>	<70;≥70	Not mentioned.	Not mentioned	1-year mortality rate 5-year RS	Not clear	29,572	<u>Stage (TNM classification)</u> <table border="1"> <thead> <tr> <th rowspan="2">Stage</th> <th colspan="3">1-year mortality rate (95%CI)</th> </tr> <tr> <th>&lt;70 years old</th> <th>≥70 years old</th> <th>Abs. diff</th> </tr> </thead> <tbody> <tr> <td>I</td> <td>18.4 (16.6;20.3)</td> <td>36.0 (33.0;39.1)</td> <td>17.6</td> </tr> <tr> <td>II</td> <td>35.8 (32.9;38.7)</td> <td>51.5 (47.7;55.3)</td> <td>15.7</td> </tr> <tr> <td>III</td> <td>52.9 (51.4;54.3)</td> <td>67.7 (65.8;69.6)</td> <td>14.8</td> </tr> <tr> <td>IV</td> <td>78.6 (77.7;79.5)</td> <td>85.3 (84.3;86.3)</td> <td>6.7</td> </tr> <tr> <td colspan="4" style="text-align: center;">5-year RS (95%CI)</td> </tr> </tbody> </table>	Stage	1-year mortality rate (95%CI)			<70 years old	≥70 years old	Abs. diff	I	18.4 (16.6;20.3)	36.0 (33.0;39.1)	17.6	II	35.8 (32.9;38.7)	51.5 (47.7;55.3)	15.7	III	52.9 (51.4;54.3)	67.7 (65.8;69.6)	14.8	IV	78.6 (77.7;79.5)	85.3 (84.3;86.3)	6.7	5-year RS (95%CI)																																																										
Stage	1-year mortality rate (95%CI)																																																																																								
	<70 years old	≥70 years old	Abs. diff																																																																																						
I	18.4 (16.6;20.3)	36.0 (33.0;39.1)	17.6																																																																																						
II	35.8 (32.9;38.7)	51.5 (47.7;55.3)	15.7																																																																																						
III	52.9 (51.4;54.3)	67.7 (65.8;69.6)	14.8																																																																																						
IV	78.6 (77.7;79.5)	85.3 (84.3;86.3)	6.7																																																																																						
5-year RS (95%CI)																																																																																									



								<table border="1"> <tbody> <tr> <td>I</td> <td>54.5 (51.9; 57.0)</td> <td>34.2 (30.3; 38.3)</td> <td>20.3</td> </tr> <tr> <td>II</td> <td>26.9 (24.2; 29.6)</td> <td>18.4 (15.0; 22.1)</td> <td>8.5</td> </tr> <tr> <td>III</td> <td>11.6 (10.6; 12.7)</td> <td>6.6 (5.5; 7.9)</td> <td>5</td> </tr> <tr> <td>IV</td> <td>3.2 (2.8; 3.6)</td> <td>2.2 (1.8; 2.6)</td> <td>1</td> </tr> </tbody> </table>	I	54.5 (51.9; 57.0)	34.2 (30.3; 38.3)	20.3	II	26.9 (24.2; 29.6)	18.4 (15.0; 22.1)	8.5	III	11.6 (10.6; 12.7)	6.6 (5.5; 7.9)	5	IV	3.2 (2.8; 3.6)	2.2 (1.8; 2.6)	1																																						
I	54.5 (51.9; 57.0)	34.2 (30.3; 38.3)	20.3																																																											
II	26.9 (24.2; 29.6)	18.4 (15.0; 22.1)	8.5																																																											
III	11.6 (10.6; 12.7)	6.6 (5.5; 7.9)	5																																																											
IV	3.2 (2.8; 3.6)	2.2 (1.8; 2.6)	1																																																											
Eberle et al., 2015 <sup>42</sup>	15–59; 60–69; 70–79; ≥80	Date of cancer diagnosis	December 31, 2010	5-year RS	Ederer II; Period analysis	132,612	<u>Sex</u>	<table border="1"> <thead> <tr> <th colspan="4">5-year RS (SE)</th> </tr> <tr> <th></th> <th>60-69 years old</th> <th>≥80 years old</th> <th>Abs. diff</th> </tr> </thead> <tbody> <tr> <td>Male</td> <td>17.0 (0.3)</td> <td>8.4 (0.6)</td> <td>8.6</td> </tr> <tr> <td>Female</td> <td>22.9 (0.6)</td> <td>10.6 (0.8)</td> <td>12.3</td> </tr> </tbody> </table>	5-year RS (SE)					60-69 years old	≥80 years old	Abs. diff	Male	17.0 (0.3)	8.4 (0.6)	8.6	Female	22.9 (0.6)	10.6 (0.8)	12.3																																						
5-year RS (SE)																																																														
	60-69 years old	≥80 years old	Abs. diff																																																											
Male	17.0 (0.3)	8.4 (0.6)	8.6																																																											
Female	22.9 (0.6)	10.6 (0.8)	12.3																																																											
Schulkes et al., 2017 <sup>43</sup>	18-70; 71-84; ≥85	Not mentioned.	February 1, 2016.	1-year OS	Proportion of patients alive after 1 and 2 years.	47,951	<u>Stage (TNM classification)</u>	<table border="1"> <thead> <tr> <th colspan="4">% of patients alive 1 year after diagnosis</th> </tr> <tr> <th></th> <th>18-70 years old</th> <th>≥85 years old</th> <th>Abs. diff</th> </tr> </thead> <tbody> <tr> <td>Stage I</td> <td>95</td> <td>76</td> <td>19</td> </tr> <tr> <td>Stage IV</td> <td>36</td> <td>46</td> <td>20</td> </tr> </tbody> </table>	% of patients alive 1 year after diagnosis					18-70 years old	≥85 years old	Abs. diff	Stage I	95	76	19	Stage IV	36	46	20																																						
% of patients alive 1 year after diagnosis																																																														
	18-70 years old	≥85 years old	Abs. diff																																																											
Stage I	95	76	19																																																											
Stage IV	36	46	20																																																											
<b>Non-small cell lung cancer</b>																																																														
Ries et al., 1994 <sup>44</sup>	<45; 45-64; 65-74; ≥75	Cancer diagnosis	Not mentioned	5-year RS	Ederer I	43,132	<u>Sex and Stage (TNM classification)</u>	<table border="1"> <thead> <tr> <th rowspan="3">Stage</th> <th colspan="6">5-year RS</th> </tr> <tr> <th colspan="3">Male</th> <th colspan="3">Female</th> </tr> <tr> <th>45-64 years old</th> <th>≥75 years old</th> <th>Abs. diff</th> <th>45-64 years old</th> <th>≥75 years old</th> <th>Abs. diff</th> </tr> </thead> <tbody> <tr> <td>I</td> <td>53</td> <td>35</td> <td>18</td> <td>63</td> <td>44</td> <td>19</td> </tr> <tr> <td>II</td> <td>27</td> <td>16</td> <td>9</td> <td>32</td> <td>18</td> <td>14</td> </tr> <tr> <td>III</td> <td>8</td> <td>3</td> <td>5</td> <td>10</td> <td>5</td> <td>5</td> </tr> <tr> <td>IV</td> <td>1</td> <td>1</td> <td>0</td> <td>2</td> <td>0</td> <td>2</td> </tr> <tr> <td>Unknown</td> <td>10</td> <td>5</td> <td>5</td> <td>15</td> <td>10</td> <td>5</td> </tr> </tbody> </table>	Stage	5-year RS						Male			Female			45-64 years old	≥75 years old	Abs. diff	45-64 years old	≥75 years old	Abs. diff	I	53	35	18	63	44	19	II	27	16	9	32	18	14	III	8	3	5	10	5	5	IV	1	1	0	2	0	2	Unknown	10	5	5	15	10	5
Stage	5-year RS																																																													
	Male			Female																																																										
	45-64 years old	≥75 years old	Abs. diff	45-64 years old	≥75 years old	Abs. diff																																																								
I	53	35	18	63	44	19																																																								
II	27	16	9	32	18	14																																																								
III	8	3	5	10	5	5																																																								
IV	1	1	0	2	0	2																																																								
Unknown	10	5	5	15	10	5																																																								

Sigel et al., 2009 <sup>45</sup>	<60;61-69; 70-79; ≥80	Cancer diagnosis	December 31, 2014	5-year RS for resected patients 2-year RS for unresected patients	Hakulin en	29,821	<u>Sex</u>	<table border="1"> <tr> <td></td> <td>&lt;60 years old</td> <td>≥80 years old</td> <td>Abs. diff</td> </tr> <tr> <td colspan="4" style="text-align: center;">Resected: 5 year RS</td> </tr> <tr> <td>Males</td> <td>69.2 (66.7–71.6)</td> <td>63.5 (56.6–70.4)</td> <td>5.7</td> </tr> <tr> <td>Females</td> <td>78.5 (76.4–80.6)</td> <td>78.1 (72.0–84.2)</td> <td>0.4</td> </tr> <tr> <td colspan="4" style="text-align: center;">Unresected: 2-year RS</td> </tr> <tr> <td>Males</td> <td>53.4 (45.2–61.7)</td> <td>51.1 (45.1–57.3)</td> <td>2.3</td> </tr> <tr> <td>Females</td> <td>55.4 (45.1–65.7)</td> <td>59.6 (53.8–65.4)</td> <td>-4.2</td> </tr> </table>				<60 years old	≥80 years old	Abs. diff	Resected: 5 year RS				Males	69.2 (66.7–71.6)	63.5 (56.6–70.4)	5.7	Females	78.5 (76.4–80.6)	78.1 (72.0–84.2)	0.4	Unresected: 2-year RS				Males	53.4 (45.2–61.7)	51.1 (45.1–57.3)	2.3	Females	55.4 (45.1–65.7)	59.6 (53.8–65.4)	-4.2
									<60 years old	≥80 years old	Abs. diff																											
								Resected: 5 year RS																														
								Males	69.2 (66.7–71.6)	63.5 (56.6–70.4)	5.7																											
								Females	78.5 (76.4–80.6)	78.1 (72.0–84.2)	0.4																											
Unresected: 2-year RS																																						
Males	53.4 (45.2–61.7)	51.1 (45.1–57.3)	2.3																																			
Females	55.4 (45.1–65.7)	59.6 (53.8–65.4)	-4.2																																			
Lin et al., 2012 <sup>46</sup>	18-69; ≥70	Cancer diagnosis	December 31, 2010	OS	Kaplan-Meier	2,231	<u>Treatment: surgery alone vs. surgery + adjuvant therapy</u>  No numerical estimates available from the paper or the author.  <i>The age disparities was bigger for patients who received only surgery than for patients who received surgery associated with adjuvant chemotherapy.</i>																															
van der Drift et al., 2012 <sup>18</sup>	<75; ≥75	Cancer diagnosis	January 1, 2010	5-year RS for stages I and II 3-year RS for stages IIIa and b	Hakulin en; cohort analysis for the period 1989-2003; period analysis for the period 2004-2009	147,760	<u>Stage (TNM classification)</u>  No numerical estimates available from the paper or the author.  <i>Results given for different treatment strategies: surgery associated to adjuvant therapy, radiotherapy, chemoradiation, and chemotherapy.</i>  <i>About stages I and II: Five years after diagnosis, the age difference was smaller for patients with stage II cancer than for those with stage I cancer, regardless treatment.</i>  <i>About stages IIIa and IIIb: Three years after diagnosis, the age difference was smaller in patients with stage IIIb cancer than in those with stage IIIa cancer.</i>																															

Langer et al., 2014 <sup>47</sup>	65-74; ≥75	First prescription of carboplatin, paclitaxel, or bevacizumab	December 31, 2011	1,2 – year OS	Kaplan-Meier	1,706	<p>Chemotherapy regimen: bevacizumab–carboplatin–paclitaxel (BCP) vs. carboplatin–paclitaxel (CP)</p> <table border="1" data-bbox="1234 305 1915 542"> <thead> <tr> <th></th> <th>65-74 years old</th> <th>≥75 years old</th> <th>Abs. diff</th> </tr> </thead> <tbody> <tr> <td colspan="4" style="text-align: center;">1-year OS (95% CI)</td> </tr> <tr> <td>BCP</td> <td>45.11 (40.27-50.53)</td> <td>43.79 (37.63-50.96)</td> <td>1.3</td> </tr> <tr> <td>CP</td> <td>36.91 (36.02-43.55)</td> <td>34.67 (30.62-39.26)</td> <td>2.2</td> </tr> <tr> <td colspan="4" style="text-align: center;">2-year OS (95% CI)</td> </tr> <tr> <td>BCP</td> <td>18.05 (14.48–22.49)</td> <td>18.85 (14.28–24.89)</td> <td>-0.8</td> </tr> <tr> <td>CP</td> <td>21.06 (18.15–24.45)</td> <td>17.83 (14.68–21.65)</td> <td>3.3</td> </tr> </tbody> </table>		65-74 years old	≥75 years old	Abs. diff	1-year OS (95% CI)				BCP	45.11 (40.27-50.53)	43.79 (37.63-50.96)	1.3	CP	36.91 (36.02-43.55)	34.67 (30.62-39.26)	2.2	2-year OS (95% CI)				BCP	18.05 (14.48–22.49)	18.85 (14.28–24.89)	-0.8	CP	21.06 (18.15–24.45)	17.83 (14.68–21.65)	3.3
	65-74 years old	≥75 years old	Abs. diff																																
1-year OS (95% CI)																																			
BCP	45.11 (40.27-50.53)	43.79 (37.63-50.96)	1.3																																
CP	36.91 (36.02-43.55)	34.67 (30.62-39.26)	2.2																																
2-year OS (95% CI)																																			
BCP	18.05 (14.48–22.49)	18.85 (14.28–24.89)	-0.8																																
CP	21.06 (18.15–24.45)	17.83 (14.68–21.65)	3.3																																
Driessen et al., 2017 <sup>48</sup>	<70; ≥70	Cancer diagnosis	February 1, 2016	Median RS months	Not mentioned	187,315	<p>Stage (TNM classification)</p> <table border="1" data-bbox="1194 641 1955 846"> <thead> <tr> <th rowspan="2">Period 2005-2009</th> <th colspan="2">Median RS months (95%CI)</th> <th rowspan="2">Abs. diff</th> </tr> <tr> <th>&lt;70</th> <th>≥70</th> </tr> </thead> <tbody> <tr> <td>I</td> <td>85 (82-92)</td> <td>34 (32-37)</td> <td>51</td> </tr> <tr> <td>II</td> <td>38 (33-43)</td> <td>18 (16-19)</td> <td>20</td> </tr> <tr> <td>III</td> <td>14 (13-14)</td> <td>8.1 (7.7-8.4)</td> <td>6</td> </tr> <tr> <td>IV</td> <td>5.3 (5.2-5.5)</td> <td>3.2 (3.1-3.4)</td> <td>2.1</td> </tr> </tbody> </table>	Period 2005-2009	Median RS months (95%CI)		Abs. diff	<70	≥70	I	85 (82-92)	34 (32-37)	51	II	38 (33-43)	18 (16-19)	20	III	14 (13-14)	8.1 (7.7-8.4)	6	IV	5.3 (5.2-5.5)	3.2 (3.1-3.4)	2.1						
Period 2005-2009	Median RS months (95%CI)		Abs. diff																																
	<70	≥70																																	
I	85 (82-92)	34 (32-37)	51																																
II	38 (33-43)	18 (16-19)	20																																
III	14 (13-14)	8.1 (7.7-8.4)	6																																
IV	5.3 (5.2-5.5)	3.2 (3.1-3.4)	2.1																																

Driessen et al., 2018 <sup>49</sup>	65-74; ≥75	Cancer diagnosis	February 1, 2017	Median OS months; 1, 3-year OS	Kaplan-Meier	7,039	<p><u>Stage (TNM classification)</u></p> <p><i>Results given for different treatment strategies: chemoradiotherapy, surgery, radiotherapy, chemotherapy, and Best Supportive Care.</i></p> <table border="1" data-bbox="1108 362 2013 833"> <thead> <tr> <th rowspan="2"></th> <th colspan="3">Stage IIIA</th> <th colspan="3">Stage IIIB</th> </tr> <tr> <th>65-74 years old</th> <th>≥75 years old</th> <th>Abs. diff</th> <th>65-74 years old</th> <th>≥75 years old</th> <th>Abs. diff</th> </tr> </thead> <tbody> <tr> <td></td> <td colspan="6" style="text-align: center;">1-year OS (95% CI)</td> </tr> <tr> <td>Chemoradiotherapy</td> <td>73 (70-76)</td> <td>66 (62-71)</td> <td>7</td> <td>68 (65-71)</td> <td>61 (55-67)</td> <td>7</td> </tr> <tr> <td>Surgery</td> <td>75 (71-79)</td> <td>69 (62-75)</td> <td>6</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Radiotherapy</td> <td>48 (41-55)</td> <td>46 (41-50)</td> <td>2</td> <td>28 (20-35)</td> <td>32 (27-37)</td> <td>-4</td> </tr> <tr> <td>Chemotherapy</td> <td>41 (35-48)</td> <td>35 (27-42)</td> <td>6</td> <td>34 (29-38)</td> <td>32 (25-39)</td> <td>2</td> </tr> <tr> <td>BSC</td> <td>21 (17-26)</td> <td>19 (16-22)</td> <td>2</td> <td>11 (8.0-14)</td> <td>13 (10-16)</td> <td>-2</td> </tr> <tr> <td></td> <td colspan="6" style="text-align: center;">3-year OS (95% CI)</td> </tr> <tr> <td>Chemoradiotherapy</td> <td>31 (28-34)</td> <td>26 (22-30)</td> <td>5</td> <td>26 (23-29)</td> <td>21 (16-26)</td> <td>5</td> </tr> <tr> <td>Surgery</td> <td>44 (40-49)</td> <td>35 (29-41)</td> <td>9</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Radiotherapy</td> <td>16 (11-21)</td> <td>11 (7.9-14)</td> <td>5</td> <td>4.4 (1.0-7.8)</td> <td>6.1 (3.4-8.9)</td> <td>-2</td> </tr> <tr> <td>Chemotherapy</td> <td>11 (6.6-15)</td> <td>6.3 (2.3-10)</td> <td>5</td> <td>7.1 (4.5-9.7)</td> <td>6.8 (2.9-11.0)</td> <td>0</td> </tr> <tr> <td>BSC</td> <td>3.9 (1.7-6.1)</td> <td>3.3 (2.0-4.8)</td> <td>1</td> <td>1.8 (0.5-3.2)</td> <td>1.1 (0.3-1.9)</td> <td>1</td> </tr> </tbody> </table>		Stage IIIA			Stage IIIB			65-74 years old	≥75 years old	Abs. diff	65-74 years old	≥75 years old	Abs. diff		1-year OS (95% CI)						Chemoradiotherapy	73 (70-76)	66 (62-71)	7	68 (65-71)	61 (55-67)	7	Surgery	75 (71-79)	69 (62-75)	6				Radiotherapy	48 (41-55)	46 (41-50)	2	28 (20-35)	32 (27-37)	-4	Chemotherapy	41 (35-48)	35 (27-42)	6	34 (29-38)	32 (25-39)	2	BSC	21 (17-26)	19 (16-22)	2	11 (8.0-14)	13 (10-16)	-2		3-year OS (95% CI)						Chemoradiotherapy	31 (28-34)	26 (22-30)	5	26 (23-29)	21 (16-26)	5	Surgery	44 (40-49)	35 (29-41)	9				Radiotherapy	16 (11-21)	11 (7.9-14)	5	4.4 (1.0-7.8)	6.1 (3.4-8.9)	-2	Chemotherapy	11 (6.6-15)	6.3 (2.3-10)	5	7.1 (4.5-9.7)	6.8 (2.9-11.0)	0	BSC	3.9 (1.7-6.1)	3.3 (2.0-4.8)	1	1.8 (0.5-3.2)	1.1 (0.3-1.9)	1
	Stage IIIA			Stage IIIB																																																																																																				
	65-74 years old	≥75 years old	Abs. diff	65-74 years old	≥75 years old	Abs. diff																																																																																																		
	1-year OS (95% CI)																																																																																																							
Chemoradiotherapy	73 (70-76)	66 (62-71)	7	68 (65-71)	61 (55-67)	7																																																																																																		
Surgery	75 (71-79)	69 (62-75)	6																																																																																																					
Radiotherapy	48 (41-55)	46 (41-50)	2	28 (20-35)	32 (27-37)	-4																																																																																																		
Chemotherapy	41 (35-48)	35 (27-42)	6	34 (29-38)	32 (25-39)	2																																																																																																		
BSC	21 (17-26)	19 (16-22)	2	11 (8.0-14)	13 (10-16)	-2																																																																																																		
	3-year OS (95% CI)																																																																																																							
Chemoradiotherapy	31 (28-34)	26 (22-30)	5	26 (23-29)	21 (16-26)	5																																																																																																		
Surgery	44 (40-49)	35 (29-41)	9																																																																																																					
Radiotherapy	16 (11-21)	11 (7.9-14)	5	4.4 (1.0-7.8)	6.1 (3.4-8.9)	-2																																																																																																		
Chemotherapy	11 (6.6-15)	6.3 (2.3-10)	5	7.1 (4.5-9.7)	6.8 (2.9-11.0)	0																																																																																																		
BSC	3.9 (1.7-6.1)	3.3 (2.0-4.8)	1	1.8 (0.5-3.2)	1.1 (0.3-1.9)	1																																																																																																		
Driessen et al., 2019 <sup>50</sup>	65-74; ≥75	Cancer diagnosis	February 1, 2018	Median OS months; 1, 5-year OS	Kaplan-Meier	12,182	<p><u>Stage (TNM classification)</u></p> <p><i>Results are given for different treatment strategies: Video Assisted Thoracic Surgery (VATS), thoracotomy, Stereotactic Body Radiotherapy (SBRT), conventional radiotherapy, and Best Supportive Care.</i></p> <table border="1" data-bbox="1108 1052 2013 1343"> <thead> <tr> <th rowspan="2"></th> <th colspan="3">Stage I</th> <th colspan="3">Stage II</th> </tr> <tr> <th>65-74 years old</th> <th>≥75 years old</th> <th>Abs. diff</th> <th>65-74 years old</th> <th>≥75 years old</th> <th>Abs. diff</th> </tr> </thead> <tbody> <tr> <td></td> <td colspan="6" style="text-align: center;">1-year OS (95% CI)</td> </tr> <tr> <td>VATS</td> <td>93 (92-94)</td> <td>89 (86-91)</td> <td>4</td> <td>85 (81-88)</td> <td>80 (75-86)</td> <td>5</td> </tr> <tr> <td>Thoracotomy</td> <td>90 (88-91)</td> <td>84 (80-87)</td> <td>6</td> <td>81 (78-84)</td> <td>76 (72-80)</td> <td>5</td> </tr> <tr> <td>SBRT</td> <td>89 (88-91)</td> <td>86 (84-87)</td> <td>3</td> <td>80 (72-89)</td> <td>82 (76-87)</td> <td>-2</td> </tr> </tbody> </table>		Stage I			Stage II			65-74 years old	≥75 years old	Abs. diff	65-74 years old	≥75 years old	Abs. diff		1-year OS (95% CI)						VATS	93 (92-94)	89 (86-91)	4	85 (81-88)	80 (75-86)	5	Thoracotomy	90 (88-91)	84 (80-87)	6	81 (78-84)	76 (72-80)	5	SBRT	89 (88-91)	86 (84-87)	3	80 (72-89)	82 (76-87)	-2																																																								
	Stage I			Stage II																																																																																																				
	65-74 years old	≥75 years old	Abs. diff	65-74 years old	≥75 years old	Abs. diff																																																																																																		
	1-year OS (95% CI)																																																																																																							
VATS	93 (92-94)	89 (86-91)	4	85 (81-88)	80 (75-86)	5																																																																																																		
Thoracotomy	90 (88-91)	84 (80-87)	6	81 (78-84)	76 (72-80)	5																																																																																																		
SBRT	89 (88-91)	86 (84-87)	3	80 (72-89)	82 (76-87)	-2																																																																																																		

								Conventional RT	79 (75–84)	78 (74–82)	1	66 (59–73)	57 (52–62)	9
								BSC	55 (50–61)	45 (42–49)	10	18 (12–24)	25 (22–30)	-7
								5-year OS (95% CI)						
								VATS	64 (62–67)	53 (49–58)	11	45 (39–50)	43 (36–51)	2
								Thoracotomy	59 (56–62)	46 (42–51)	13	46 (42–50)	29 (24–34)	17
								SBRT	40 (36–43)	30 (27–33)	10	33 (22–45)	27 (19–36)	6
								Conventional RT	27 (21–33)	20 (16–25)	7	14 (8.2–21)	6.7 (3.7–9.6)	7
								BSC	17 (12–21)	8.8 (6.5–11)	8	3.8 (0.7–6.9)	2.3 (0.7–3.9)	2

Small cell lung cancer																										
Janssen-Heijnen et al., 1998 <sup>51</sup>	<70; ≥70	Not mentioned.	April, 1994	Median RS months conditioning on surviving the 1st month after diagnosis	Hakulin en	319	<p><b>Stage:</b></p> <ul style="list-style-type: none"> <li>- Limited: confined to one hemithorax including hilar, ipsilateral and contralateral mediastinal, and ipsilateral and contralateral supraclavicular lymph nodes</li> <li>- Extensive: any disease at sites beyond the definition of limited disease</li> <li>- Unknown</li> </ul> <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th rowspan="2">Stage</th> <th colspan="3">median RS months for the period 1990-1992</th> </tr> <tr> <th>&lt;70 years old</th> <th>≥70 years old</th> <th>Abs. diff</th> </tr> </thead> <tbody> <tr> <td>Limited</td> <td>13</td> <td>10</td> <td>3</td> </tr> <tr> <td>Extensive</td> <td>8</td> <td>5</td> <td>3</td> </tr> <tr> <td>Unknown</td> <td>8</td> <td>3</td> <td>5</td> </tr> </tbody> </table>	Stage	median RS months for the period 1990-1992			<70 years old	≥70 years old	Abs. diff	Limited	13	10	3	Extensive	8	5	3	Unknown	8	3	5
Stage	median RS months for the period 1990-1992																									
	<70 years old	≥70 years old	Abs. diff																							
Limited	13	10	3																							
Extensive	8	5	3																							
Unknown	8	3	5																							

Janssen-Heijnen et al., 2012 <sup>19</sup>	45-59; 60-74; ≥75	Cancer diagnosis	January 1, 2010	1,3, 5, 10 - year RS	Hakulin en; Period analysis	34,100	<p><u>Sex</u></p> <table border="1" data-bbox="1241 305 1913 646"> <thead> <tr> <th rowspan="2">Period 2004-2009</th> <th colspan="3">1-year RS</th> </tr> <tr> <th>45-59 years old</th> <th>≥75 years old</th> <th>Abs. Diff</th> </tr> </thead> <tbody> <tr> <td>Male</td> <td>41</td> <td>20</td> <td>21</td> </tr> <tr> <td>Female</td> <td>47</td> <td>19</td> <td>18</td> </tr> <tr> <td></td> <th colspan="3">3-year RS</th> </tr> <tr> <td>Male</td> <td>9</td> <td>4</td> <td>5</td> </tr> <tr> <td>Female</td> <td>14</td> <td>6</td> <td>8</td> </tr> <tr> <td></td> <th colspan="3">5-year RS</th> </tr> <tr> <td>Male</td> <td>6</td> <td>3</td> <td>3</td> </tr> <tr> <td>Female</td> <td>11</td> <td>4</td> <td>7</td> </tr> </tbody> </table>	Period 2004-2009	1-year RS			45-59 years old	≥75 years old	Abs. Diff	Male	41	20	21	Female	47	19	18		3-year RS			Male	9	4	5	Female	14	6	8		5-year RS			Male	6	3	3	Female	11	4	7																											
Period 2004-2009	1-year RS																																																																								
	45-59 years old	≥75 years old	Abs. Diff																																																																						
Male	41	20	21																																																																						
Female	47	19	18																																																																						
	3-year RS																																																																								
Male	9	4	5																																																																						
Female	14	6	8																																																																						
	5-year RS																																																																								
Male	6	3	3																																																																						
Female	11	4	7																																																																						
Wang et al., 2017 <sup>52</sup>	<50; 50-59; 60-69; 70-79; ≥80	Not mentioned.	Not mentioned	CSS	Kaplan-Meier	16,503	<p><u>Stage (TNM classification); Surgery vs. no surgery; Radiation vs. no radiation</u></p> <table border="1" data-bbox="1157 711 1997 1076"> <thead> <tr> <th rowspan="2"></th> <th colspan="3">1-year CSS</th> <th colspan="3">3-year CSS (2-year CSS for stage IV)</th> </tr> <tr> <th>50-59</th> <th>≥80</th> <th>Abs. diff</th> <th>50-59</th> <th>≥80</th> <th>Abs. diff</th> </tr> </thead> <tbody> <tr> <td>Stage III</td> <td>67.5</td> <td>36.2</td> <td>31.3</td> <td>29.1</td> <td>8.0</td> <td>21.1</td> </tr> <tr> <td>Stage IV</td> <td>31.3</td> <td>11.7</td> <td>19.6</td> <td>10.3</td> <td>4.0</td> <td>6.3</td> </tr> <tr> <td></td> <th colspan="3">1-year CSS</th> <td colspan="3" rowspan="2" style="background-color: #cccccc;"></td> </tr> <tr> <td>Surgery</td> <td>82.6</td> <td>45</td> <td>37.6</td> </tr> <tr> <td>No surgery</td> <td>42.2</td> <td>20.5</td> <td>21.7</td> <td colspan="3"></td> </tr> <tr> <td></td> <th colspan="3">1-year CSS</th> <th colspan="3">3-year CCS</th> </tr> <tr> <td>Radiation</td> <td>52.3</td> <td>33.4</td> <td>18.9</td> <td>17.4</td> <td>8.6</td> <td>8.8</td> </tr> <tr> <td>No radiation</td> <td>28.6</td> <td>15</td> <td>13.6</td> <td>5.5</td> <td>3.4</td> <td>2.1</td> </tr> </tbody> </table>		1-year CSS			3-year CSS (2-year CSS for stage IV)			50-59	≥80	Abs. diff	50-59	≥80	Abs. diff	Stage III	67.5	36.2	31.3	29.1	8.0	21.1	Stage IV	31.3	11.7	19.6	10.3	4.0	6.3		1-year CSS						Surgery	82.6	45	37.6	No surgery	42.2	20.5	21.7					1-year CSS			3-year CCS			Radiation	52.3	33.4	18.9	17.4	8.6	8.8	No radiation	28.6	15	13.6	5.5	3.4	2.1
	1-year CSS			3-year CSS (2-year CSS for stage IV)																																																																					
	50-59	≥80	Abs. diff	50-59	≥80	Abs. diff																																																																			
Stage III	67.5	36.2	31.3	29.1	8.0	21.1																																																																			
Stage IV	31.3	11.7	19.6	10.3	4.0	6.3																																																																			
	1-year CSS																																																																								
Surgery	82.6	45	37.6																																																																						
No surgery	42.2	20.5	21.7																																																																						
	1-year CSS			3-year CCS																																																																					
Radiation	52.3	33.4	18.9	17.4	8.6	8.8																																																																			
No radiation	28.6	15	13.6	5.5	3.4	2.1																																																																			

Abs. diff: Absolute difference; CSS: cancer-specific survival; NS: Net survival; OS: overall survival; RS: Relative survival  
 N.B.: Extraction restricted to data related to factors of age disparities in survival/mortality

## References

1. Bassily, M. N., Wilson, R., Pompei, F. & Burmistrov, D. Cancer survival as a function of age at diagnosis: a study of the Surveillance, Epidemiology and End Results database. *Cancer Epidemiol* **34**, 667–681 (2010).
2. Quaglia, A. *et al.* The cancer survival gap between elderly and middle-aged patients in Europe is widening. *Eur. J. Cancer* **45**, 1006–1016 (2009).
3. Brenner, H. & Arndt, V. Recent increase in cancer survival according to age: higher survival in all age groups, but widening age gradient. *Cancer Causes Control* **15**, 903–910 (2004).
4. De Angelis, R. *et al.* Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. *Lancet Oncol.* **15**, 23–34 (2014).
5. Colonna, M., Bossard, N., Remontet, L., Grosclaude, P. & FRANCIM Network. Changes in the risk of death from cancer up to five years after diagnosis in elderly patients: a study of five common cancers. *Int. J. Cancer* **127**, 924–931 (2010).
6. Zeng, C. *et al.* Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010. *JAMA Oncol* **1**, 88–96 (2015).
7. Arnold, M. *et al.* Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. *Lancet Oncol.* **20**, 1493–1505 (2019).
8. Balducci, L. Studying cancer treatment in the elderly patient population. *Cancer Control* **21**, 215–220 (2014).
9. Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A. & Albain, K. S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. *N. Engl. J. Med.* **341**, 2061–2067 (1999).
10. Lewis, J. H. *et al.* Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials. *JCO* **21**, 1383–1389 (2003).
11. Shahrokni, A. *et al.* The association between social support and chemotherapy-related toxicity in older patients with cancer. *J Geriatr Oncol* (2019) doi:10.1016/j.jgo.2019.08.015.
12. Williams, G. R. *et al.* Unmet social support needs among older adults with cancer. *Cancer* **125**, 473–481 (2019).
13. Galvin, A. *et al.* Sociodemographic, socioeconomic, and clinical determinants of survival in patients with cancer: A systematic review of the literature focused on the elderly. *Journal of Geriatric Oncology* **9**, 6–14 (2018).
14. Pilleron, S. *et al.* Global cancer incidence in older adults, 2012 and 2035: A population-based study. *Int. J. Cancer* **144**, 49–58 (2019).
15. Janssen-Heijnen M.L.G. *et al.* Clinical relevance of conditional survival of cancer patients in Europe: Age-specific analyses of 13 cancers. *J. Clin. Oncol.* **28**, 2520–2528 (2010).
16. van den Broek, C. B. M. *et al.* The survival gap between middle-aged and elderly colon cancer patients. Time trends in treatment and survival. *Eur J Surg Oncol* **37**, 904–912 (2011).
17. Kolfshoten N.E. *et al.* Nonelective colon cancer resections in elderly patients: Results from the dutch surgical colorectal audit. *Dig. Surg.* **29**, 412–419 (2012).
18. van der Drift, M. A. *et al.* Progress in Standard of Care Therapy and Modest Survival Benefits in the Treatment of Non-small Cell Lung Cancer Patients in the Netherlands in the Last 20 Years. *Journal of Thoracic Oncology* **7**, 291–298 (2012).
19. Janssen-Heijnen, M. L. G. *et al.* Modest Improvements of Survival for Patients with

- Small Cell Lung Cancer Aged 45 to 59 Years Only, Diagnosed in the Netherlands, 1989 to 2008. *Journal of Thoracic Oncology* **7**, 227–232 (2012).
20. Brungs D. *et al.* Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer. *Clin. Colorectal Cancer* **17**, e549–e555 (2018).
  21. van de Schans S.A.M. *et al.* COPD in cancer patients: Higher prevalence in the elderly, a different treatment strategy in case of primary tumours above the diaphragm, and a worse overall survival in the elderly patient. *Eur. J. Cancer* **43**, 2194–2202 (2007).
  22. Hayden, J. A., van der Windt, D. A., Cartwright, J. L., Côté, P. & Bombardier, C. Assessing bias in studies of prognostic factors. *Ann. Intern. Med.* **158**, 280–286 (2013).
  23. Altman, D. G., De Stavola, B. L., Love, S. B. & Stepniowska, K. A. Review of survival analyses published in cancer journals. *Br. J. Cancer* **72**, 511–518 (1995).
  24. Ouzzani, M., Hammady, H., Fedorowicz, Z. & Elmagarmid, A. Rayyan-a web and mobile app for systematic reviews. *Syst Rev* **5**, 210 (2016).
  25. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* **6**, e1000097 (2009).
  26. Yancik R. *et al.* Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: A population-based study. *Cancer* **82**, 2123–2134 (1998).
  27. van Steenbergen, L. N. *et al.* Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in The Netherlands 1989-2006. *Annals of Oncology* **21**, 2206–2212 (2010).
  28. Nedrebo B.S. *et al.* Survival effect of implementing national treatment strategies for curatively resected colonic and rectal cancer. *Br. J. Surg.* **98**, 716–723 (2011).
  29. Majek, O. *et al.* Sex Differences in Colorectal Cancer Survival: Population-Based Analysis of 164,996 Colorectal Cancer Patients in Germany. *Plos One* **8**, e68077 (2013).
  30. Van Steenbergen L.N. *et al.* Minimal excess mortality for long-term colon cancer survivors in the Netherlands 1989-2008. *Eur. J. Cancer* **49**, 585–592 (2013).
  31. Khan H., Olszewski A.J. & Somasundar P. Lymph node involvement in colon cancer patients decreases with age; a population based analysis. *Eur. J. Surg. Oncol.* **40**, 1474–1480 (2014).
  32. Aan De Stegge W.B., Van Leeuwen B.L., Elferink M.A.G. & De Bock G.H. The Evaluation of more lymph nodes in colon cancer is associated with improved survival in patients of all ages. *PLoS ONE* **11**, e0155608 (2016).
  33. Hines, R. B., Bimali, M., Johnson, A. M., Bayakly, A. R. & Collins, T. C. Prevalence and survival benefit of adjuvant chemotherapy in stage III colon cancer patients: Comparison of overall and age-stratified results by multivariable modeling and propensity score methodology in a population-based cohort. *Cancer Epidemiol* **44**, 77–83 (2016).
  34. Aquina, C. T. *et al.* The impact of age on complications, survival, and cause of death following colon cancer surgery. *British Journal of Cancer* **116**, 389–397 (2017).
  35. Hur, H., Oh, C.-M., Won, Y.-J., Oh, J. H. & Kim, N. K. Characteristics and Survival of Korean Patients With Colorectal Cancer Based on Data From the Korea Central Cancer Registry Data. *Annals of Coloproctology* **34**, 212–221 (2018).
  36. Park H.-C. *et al.* Data on the characteristics and the survival of Korean patients with colorectal cancer from the Korea Central Cancer Registry. *Annals Coloproctology* **29**, 144–149 (2013).
  37. Wingo, P. A., Ries, L. A. G., Parker, S. L. & Heath, C. W. Long-term cancer patient survival in the United States. *Cancer Epidemiology Biomarkers & Prevention* **7**, 271–282 (1998).



38. Chang, C.-M. *et al.* The Combined Effect of Individual and Neighborhood Socioeconomic Status on Cancer Survival Rates. *Plos One* **7**, e44325 (2012).
39. Jung K.-W. *et al.* Survival of Korean adult cancer patients by stage at diagnosis, 2006-2010: National cancer registry study. *Cancer Res. Treat.* **45**, 162–171 (2013).
40. Maringe, C., Li, R., Mangtani, P., Coleman, M. P. & Rachet, B. Cancer survival differences between South Asians and non-South Asians of England in 1986-2004, accounting for age at diagnosis and deprivation. *British Journal of Cancer* **113**, 173–181 (2015).
41. Petera, J., Dušek, L., Sirák, I., Soumarova, R. & Jarkovsky, J. Cancer in the elderly in the Czech Republic. *Eur J Cancer Care (Engl)* **24**, 163–178 (2015).
42. Eberle, A. *et al.* Lung cancer survival in Germany: A population-based analysis of 132,612 lung cancer patients. *Lung Cancer* **90**, 528–533 (2015).
43. Schulkes K.J.G. *et al.* Lung Cancer in the Oldest Old: A Nation-Wide Study in The Netherlands. *Lung* **195**, 627–634 (2017).
44. RIES, L. INFLUENCE OF EXTENT OF DISEASE, HISTOLOGY, AND DEMOGRAPHIC-FACTORS ON LUNG-CANCER SURVIVAL IN THE SEER POPULATION-BASED DATA. *Seminars in Surgical Oncology* **10**, 21–30 (1994).
45. Sigel, K., Bonomi, M., Packer, S. & Wisnivesky, J. Effect of age on survival of clinical stage I non-small-cell lung cancer. *Ann. Surg. Oncol.* **16**, 1912–1917 (2009).
46. Lin, Z.-Z. *et al.* Survival Following Surgery with or without Adjuvant Chemotherapy for Stage I-III A Non-Small Cell Lung Cancer: An East Asian Population-Based Study. *Oncologist* **17**, 1294–1302 (2012).
47. Langer C. *et al.* Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: A retrospective cohort study. *Lung Cancer* **86**, 350–357 (2014).
48. Driessen E.J., Aarts M.J., Bootsma G.P., van Loon J.G. & Janssen-Heijnen M.L. Trends in treatment and relative survival among Non-Small Cell Lung Cancer patients in the Netherlands (1990-2014): Disparities between younger and older patients. *Lung Cancer* **108**, 198–204 (2017).
49. Driessen E.J.M. *et al.* Patterns of treatment and survival among older patients with stage III non-small cell lung cancer. *Lung Cancer* **116**, 55–61 (2018).
50. Driessen E. *et al.* Population-based patterns of treatment and survival for patients with stage I and II non-small cell lung cancer aged 65-74years and 75years or older. *J. Geriatr. Oncol.* **10**, 547–554 (2019).
51. Janssen-Heijnen, M. L. G., Schipper, R. M., Klinkhamer, P., Crommelin, M. A. & Coebergh, J. W. W. Improvement and plateau in survival of small-cell lung cancer since 1975: A population-based study. *Annals of Oncology* **9**, 543–547 (1998).
52. Wang, H. *et al.* Better cancer specific survival in young small cell lung cancer patients especially with AJCC stage III. *Oncotarget* **8**, 34923–34934 (2017).
53. Dickman, P. W. *et al.* Survival of cancer patients in Finland 1955-1994. *Acta Oncol* **38 Suppl 12**, 1–103 (1999).
54. Mariotto, A. B. *et al.* Cancer survival: an overview of measures, uses, and interpretation. *J. Natl. Cancer Inst. Monographs* **2014**, 145–186 (2014).
57. Schmoll, H. J. *et al.* ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. *Ann. Oncol.* **23**, 2479–2516 (2012).
58. Merchant, S. J. *et al.* Management of stage III colon cancer in the elderly: Practice patterns and outcomes in the general population. *Cancer* **123**, 2840–2849 (2017).
59. Raycraft, T. *et al.* Causes of mortality in older patients with stage 3 colon cancer. *J Geriatr Oncol* **10**, 138–142 (2019).

60. Sarasqueta, C. *et al.* Impact of age on the use of adjuvant treatments in patients undergoing surgery for colorectal cancer: patients with stage III colon or stage II/III rectal cancer. *BMC Cancer* **19**, 735 (2019).
61. Van Cutsem, E. *et al.* ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann. Oncol.* **27**, 1386–1422 (2016).
62. Belot, A. *et al.* Association between age, deprivation and sepcific comorbid conditions and the receipt of major surgery in patients with non-small cell lung cancer in England: a population-based study. *Thorax* **74**, 51–59 (2019).
63. Sarfati, D., Koczwara, B. & Jackson, C. The impact of comorbidity on cancer and its treatment. *CA Cancer J Clin* **66**, 337–350 (2016).
64. Mohile, S. G. *et al.* Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. *JCO* **36**, 2326–2347 (2018).
65. Sarfati, D., Hill, S., Purdie, G., Dennett, E. & Blakely, T. How well does routine hospitalisation data capture information on comorbidity in New Zealand? *N. Z. Med. J.* **123**, 50–61 (2010).
66. Sarfati, D., Gurney, J., Stanley, J., Lim, B. T. & McSherry, C. Development of a pharmacy-based comorbidity index for patients with cancer. *Med Care* **52**, 586–593 (2014).
67. Katcoff, H., Wenzlaff, A. & Schwartz, A. Survival in women with NSCLC. *J Thorac Oncol* **9**, 355–361 (2014).
68. Townsend, E., Miller, V. & Prakash, Y. Sex differences and sex steroids in lung health and disease. *Endocrine Reviews* **33**, 1–47 (2012).
69. Hill, S. *et al.* Survival disparities in Indigenous and non-Indigenous New Zealanders with colon cancer: the role of patient comorbidity, treatment and health service factors. *J Epidemiol Community Health* **64**, 117–123 (2010).
70. Ellis, L., Coleman, M. P. & Rachet, B. How many deaths would be avoidable if socioeconomic inequalities in cancer survival in England were eliminated? A national population-based study, 1996-2006. *Eur. J. Cancer* **48**, 270–278 (2012).
71. Radkiewicz, C. *et al.* Sex and survival in non-small cell lung cancer: A nationwide cohort study. *Plos One* **14**, e0219206 (2019).
72. Belot, A. *et al.* Summarizing and communicating on survival data according to the audience: a tutorial on different measures illustrated with population-based cancer registry data. *Clin Epidemiol* **11**, 53–65 (2019).
73. Sarfati, D., Blakely, T. & Pearce, N. Measuring cancer survival in populations: relative survival vs cancer-specific survival. *Int J Epidemiol* **39**, 598–610 (2010).

2,139 references extracted  
EMBASE 430; MEDLINE  
431; SCOPUS 644; Web of  
Science 634

1,241 references  
after duplicates removed

623 retained on titles

116 retained on abstracts

39 retained on full-texts

21 additional references